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The generation of multiple, large scale genomic datasets has become increasingly common in
biological and biomedical research. These datasets can be collected for a common set of samples over
multiple assays, known as a multi-omics dataset, or for the same assay over multiple collections of
samples, known as a multi-study dataset. The growth of multi-omics datasets has given rise to many
methods that identify sources of common variation across data types. However, the unsupervised nature of
these methods makes it difficult to evaluate their performance. We propose Multi-Omics VIsualization of
Estimated contributions (MOVIE), to evaluate the extent of overfitting of multi-omics methods. MOVIE
utilizes a cross-validation approach to identify method stability and provides a visualization of the
overfitting. Plotting the contributions of one data type against another produces contribution plots, where
contributions are calculated for each subject and each data type from the results of each multi-omics
method. The usefulness of MOVIE is demonstrated through evaluating the performance of multi-omics
methods on large and small-sample experimental datasets and identifying overfitting in a permuted null
dataset.
We also propose a statistical model for comparing RNA splicing patterns from an independent
experimental dataset to a reference dataset containing a large number of samples. The relative proportion
of RNA isoforms expressed for a given gene has been associated with disease states in cancer, retinal
diseases, and neurological disorders. Examination of relative isoform proportions can help determine
biological mechanisms, but such analyses often require a per-gene investigation of splicing patterns.
Leveraging large public datasets produced by genomic consortia as a reference, one can compare splicing
patterns in a dataset of interest with those of a reference panel in which samples are divided into distinct
groups, such as tissue of origin, or disease status. Our proposed model ACTOR, A latent Dirichlet model
to Compare expressed isoform proportions TO a Reference panel, uses a variational Bayes procedure to
estimate posterior distributions for the group membership of one or more samples. Using the Genotype-
iii
Tissue Expression (GTEx) project as a reference dataset, we evaluate ACTOR on simulated and real
RNA-seq datasets to determine tissue-type classifications of genes.
In multi-omics analyses, variable sample quality of one assay can drastically alter the results. Current
methods account for this heuristically by removing samples based on a semi-arbitrary cut point of an
external quality score. Leveraging an external sample quality score, we propose Sample Quality Weighted
Canonical Correlation Analysis (SQWCCA) as an extension to Sparse Canonical Correlation Analysis.
SQWCCA calculates sample weights based on an external sample quality score which improve the
weighted correlation between the two assays. We evaluated SQWCCA through simulations and a dataset
of samples from Crohn’s disease patients and other patients who do not have inflammatory bowel disease.
In simulations, SQWCCA was able to identify poor quality samples, while avoiding the unnecessary
removal of samples when using a non-informative quality score. In the real dataset, SQWCCA identified
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CHAPTER 1: LITERATURE REVIEW
1.1 Multi-Omics Methods
Multi-omics studies are often performed when there is interest in understanding the relationship
between different biological modalities (RNA, chromatin, etc.). In some cases, it is useful to determine
the extent to which these relationships can help develop classes of samples, while in other cases it is
more informative to examine the correlations across data modalities in order to identify which modalities
are strongly associated. As data generation has become less expensive, investigators are increasingly
generating multiple -omics datasets from a common set of biological samples, thus giving rise to demand
for statistical methods to analyze the data. Certain methods, such as iCluster+ (Shen et al., 2010) and
Similarity Network Fusion (SNF) (Wang et al., 2014), classify samples into groups. These methods
use multiple -omics platforms to find similarities and differences between samples and across data
types. For example, this type of analysis has been applied to identify novel tumor subtypes. Supervised
methods such as iBoost (Wong et al., 2019) can be used to leverage multiple large-scale data types to help
predict survival time or other response variables of interest. Other methods determine which features or
biological processes contribute to the common variation across data types, as well as the magnitude of the
relationships. Examples include Sparse multiple Canonical Correlation Analysis (Sparse mCCA) (Witten
and Tibshirani, 2009), Angle-based Joint and Individual Variation Explained (AJIVE) (Feng et al., 2018),
and Multi-Omics Factor Analysis (MOFA) (Argelaguet et al., 2018). Additionally, Canonical Correlation
Analysis (CCA) (Hotelling, 1936) can be modified for a high-dimensional setting by running the analysis
on the top principal components (PCs) of each matrix. Unsupervised multi-omics methods, which do
not consider a primary outcome when detecting common variation across data types, are useful for
exploratory data analysis, including assessment of data quality as well as hypothesis generation, similar
to applications of ordination methods such as principal components analysis (PCA) for experiments
with a single data type. Sample swaps may be detected with unsupervised multi-omics methods as
outlying points in various scatter-plots described below, in the case that different data types disagree
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in the placement of individual samples in the space of common variation. The following sections will
provide deeper explanations of four popular unsupervised multi-omics methods.
1.1.1 PC-CCA
CCA (Hotelling, 1936) was developed to assess relationships between linear combinations of fea-
tures of two separate matrices. If we let ~X1 and ~X2 to be two vectors of random variables, then
CCA can be applied to identify β1 and β2 that maximizes Corr(β′1 ~X1, β
′
2
~X2) given the constraint
that V ar(β′i ~Xi) = 1. Let ΣX1X1 and ΣX2X2 be the covariance matrices for ~X1 and ~X2 respectively.













= β′1ΣX1X2β2 + λ1(β
′
1ΣX1X1 − 1) + λ2(β′2ΣX2X2 − 1)
Using Largrange multipliers, the optimization problem is solved as follows.
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Thus, we are left with β1 being an eigenvector for Σ−1X1X1ΣX1X2Σ
−1
X2X2




ΣX1X2 . This gives a closed form solution with the correlation indicating how
strongly related the two matrices are, and the vectors of weights identifying which features are closely
related. While estimates of the weights βi have a closed-form solution, CCA relies on the number of
subjects being larger than the number of features. Additionally, CCA can only accommodate two matrices,
and thus, it is not appropriate for multi-omics analyses with more than two assays. In analyses where the
datasets have a large number of features, CCA can be conducted on the top Principal Components (PCs)
of each matrix. This method is often called PC-CCA. The number of PCs to include must be decided
2
beforehand, and the number of PCs can be shown to affect how well the weights generalize. With null
datasets, correlations as high as 0.9 are possible when the number of PCs included in the analysis is large
(Figure 1.1).
Figure 1.1: CCA on PCs of null Gaussian data returns correlations as high as 0.9, for datasets of sizes
that are typical genomics (e.g. 100 samples, 5000 genes).
1.1.2 Sparse mCCA
Sparse mCCA (Witten and Tibshirani, 2009) is an extension of CCA that allows for the inclusion
of multiple high-dimensional matrices. Sparse mCCA estimates each βi by maximizing the sum of all
pair-wise weighted correlations. Additionally, Sparse mCCA imposes a sparsity parameter on the weights
through a penalty on the weights, which forces a larger proportion of the weights to be set equal to zero
and leaves only non-zero weights for features that are related across data types. These two adjustments
prevent a closed-form solution from being obtained, and thus, an iterative procedure is conducted to
estimate the weights. Let Xi be a n x dk data matrix for k = 1, ...,K different matrices. Equation 1
provides the objective function for Sparse mCCA. Pi(βi) corresponds to any convex penalty function
for the weights of matrix i with the default penalty being a lasso. The tuning parameter is calculated
using a permutation approach, in which the value that provides the smallest permutation p-value for the
sum of the correlations is selected. P values are calculated as the average number of permutations that
provide a sum of correlations greater than the observed one. Sparse mCCA can also be implemented
in a supervised setting in which there is an interest in the prediction of a separate response variable.
When only two data types are of interest, we will refer to this method as Sparse Canonical Correlation
3
Analysis (Sparse CCA). Several other methods have also attempted to create a sparse solution to CCA







i Xjβj subject to ||βi||2 ≤ 1, Pi(βi) ≤ ci (1.1)
1.1.2.1 Tuning Parameter Selection
The estimation of tuning parameters is one of the most challenging and computationally difficult
tasks in optimization problems. Several approaches examined the estimation of tuning parameters in
Sparse CCA. (Waaijenborg and Zwinderman, 2009) provided a summary of several metrics for the
selection of the tuning parameter for the feature loadings of each data type. Approaches included the
mean difference between the canonical correlation of the training and validation set (Waaijenborg et al.
(2008)), the mean absolute canonical correlation of the validation sets (Parkhomenko et al. (2007)), and
the mean squared prediction error (MSPE) of the canonical variates defined as in Equation 1.2 below,
where β−j1 and β
−j
2 are the estimated loadings in the training set excluding sample j and ρ
−j is the
canonical correlation from the same analysis. These approaches all use a k-fold cross validation to






|β′−j1 X1j − ρ
−jβ′−j2 X2j |
2 (1.2)
Additionally, Witten and Tibshirani proposed a permutation approach where the rows of one matrix
are permuted and the canonical correlation is calculated (ρj) for a large number of iterations. A p-value
is then calculated by taking the total number of permuted correlations larger than the un-permuted
correlation and dividing by the total number of permutations. The tuning parameter which provided the
smallest p-value is selected as the optimal value.
1.1.3 AJIVE
AJIVE (Feng et al., 2018) classifies the variability of each matrix as being a component of the
variation across all data types, the variation within one data type, or the result of random noise. Let Xk be
a matrix of size dk x n for k = 1, ...,K different matrices. Let Jk be the joint variation for matrix k. The
4
joint variation can be thought of as the variability which is common across all data blocks. Let Ik be the
variation unique to data block k. Then AJIVE looks to identify Jk and Ik such that Xk = Jk + Ik + Ek
where Ek corresponds to the additive noise. AJIVE requires the specification of an initial number of
the signal ranks for each matrix (rk). A Singular Value Decomposition is then applied to each data
matrix such that Xk = UkΣkV ′k . Let Ṽk be the top rk components of Vk. This represents the components
which will be classified as either joint or individual while the remaining dk − rk components are used to
characterize the additive noise. Then the Ṽk’s are stacked to form M = (Ṽ1, ..., ṼK)′. An SVD is again
conducted on M = UMΣMV ′M . The components of this SVD are thresholded using matrix perturbation
theory to determine the top signal components which will be used to characterize the joint variation
while the remaining components will characterize the individual variation. As mentioned above, AJIVE
requires the specification of an initial number of the signal ranks, and thus, requires examination of
the scree plot of each data type prior to running the software in order to make this determination. The
specification of these ranks is subjective and AJIVE can provide different conclusions based upon this
analysis.
1.1.4 MOFA
MOFA (Argelaguet et al., 2018) is a factor analysis method that estimates a series of latent factors to
describe the variation across and within data types. Let Y 1, ...YM be M data matrices of dimensions N x
Dm, where N is the number of samples. MOFA decomposes each data matrix as Y m = Z(Wm)T + εm
where Z is the N x K factor matrix common for all data matrices, Wm denotes the Dm x K weight
matrix, and εm denotes the residual noise. K corresponds to the number of latent factors in the model.
The noise is assumed to follow N(0, 1/τmd ) where d is the feature in matrix m. MOFA imposes a
Gaussian independent prior on the latent variables Z and an uninformative conjugate Gamma prior on
the precision. Sparsity is imposed on both the matrix and factor level as well as on the feature level. This
sparsity allows for MOFA to identify a solution which includes only relevant matrices and features in
each factor. It also restricts the number of factors so that the solution is of a more manageable dimension.
To impose sparsity on the matrix level and factor levels, an Automatic Relevance Determination (ARD)
prior is set for the weights. A reparameterization of the prior includes a Bernoulli random variable smd,k
which will determine if the weight for feature d in factor k of matrix m is set to 0 or estimated. The
result is given in equation 1.3. θmk follows a beta prior and α
m
k follows a gamma prior. The model is
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fit using variational Bayes inference. MOFA aims to classify variation as being common across data
types; however, unlike AJIVE, MOFA allows for the variability to be across one, some, or all data types.
MOFA requires that the specification of the total number of hidden factors to estimate or a threshold for
removing factors, which can lead to differing results. MOFA also has the ability to include samples for
which data has not been collected for all assays. This feature is particularly useful as the high cost of
collecting large sequencing data for samples may make it difficult to collect complete data.
τmd ∼ N(aT0 , bT0 )
p(wmd,k, s
m
d,k) ∼ N(wmd,k|0, 1/αmk )Ber(smd,k|θmk )
θ ∼ Beta(aθ0, bθ0)
αmk ∼ Gamma(aα0 , bα0 )
(1.3)
1.1.5 Current Comparisons of Multi-Omics Methods
Several investigators have compared the performance of multi-omics methods. For example, Meng et
al (2016) compared the mathematical properties of several multi-omics methods. Pucher et al (2019) used
simulated and experimental cancer data sets to compare methods in terms of classification and feature
overlap with known biological pathways. Additionally, Tini et al (2017) compared methods for sample
clustering. However, assessment of performance of unsupervised methods, in terms of stability of output
and degree of overfitting on experimental datasets, can be challenging. Data splitting and the projection
of estimated contributions were proposed by Soneson et al (2010) for parameter tuning and validation
of a multi-omics method. Other methods have assessed method performance by using leave-one-out
cross-validation and the projection of learned factors on new datasets (Brown et al., 2018); (Fertig et al.,
2012).
1.1.6 Summary
Methods for the analysis of multi-omics datasets are becoming increasingly more popular. PC-CCA,
Sparse mCCA, AJIVE, and MOFA are four such unsupervised methods which aim to describe variability
across biological assays. As the availability of unsupervised methods increases, the need for appropriate
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evaluation of methods is critical and can be exceptionally difficult. Several method comparisons have
been published, however there has been little work done in terms of the evaluation of methods based on
the degree of overfitting.
1.2 Multi-Study Datasets
While data collected for multiple assays across a common set of patients is referred to as a multi-
omics dataset, data collected for one modality across multiple collections of samples can be referred to
as a multi-study dataset. Meta-analysis is the most common form of a multi-study analysis, wherein
summary statistics are aggregated for multiple independent studies to increase power and avoid potential
type I errors. Multi-study analyses can also utilize large genomic databases as reference panels to identify
common patterns observed in an independent set of samples. Leveraging data from reference panels can
increase power and help with the interpretation of results from smaller studies. The remainder of this
chapter will focus on the usage of reference panels in the context of RNA splicing.
1.3 Isoform Splicing
RNA splicing is a process through which non-coding regions (introns) of pre-mRNA molecules are
removed to form mature mRNA. In this process, coding regions (exons) can also be removed creating
multiple sequences of exons which may have a different functional form in the development of proteins.
These sequences are called transcripts or isoforms. Reyes and Huber (2018) found that the majority of
isoform differences were due to alternative start and termination sites of transcription. This highlights
that the focus should be expanded beyond the splicing of internal exons and analyses should also be
conducted on the transcript level. Analyses investigating differences in total transcript expression can be
informative, but it is also of interest to investigate differences in the proportion of total gene expression
that is attributable to each transcript. This is often called transcript usage.
1.3.1 Differential Transcript Usage
Aberrant differential transcript usage (DTU) has been found to be associated with cancer (Climente-
González et al. (2017); Vitting-Seerup and Sandelin (2017)), retinal disease, and neurological disorders
(Scotti and Swanson (2016)). Isoforms are known to be differentially spliced across tissues (Saha et al.
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(2018)) with samples from the brain, pancreas, liver, and peripheral nervous system exhibiting the most
distinct alternative splicing patterns (Yeo et al. (2004)). A number of methods aimed at detecting DTU
have been developed over the years. DRIMSeq (Nowicka and Robinson (2016)), DEXSeq (Anders et al.
(2012)), and SUPPA2 (Trincado et al. (2018)) are three popular methods which identify genes that are
differentially spliced across one or more conditions.
1.3.2 DRIMSeq
DRIMSeq uses a Dirichlet multinomial distribution to model the raw isoform expression assuming
that the total gene expression per sample is a fixed quantity. The Dirichlet multinomial distribution
is a hierarchical distribution composed of a multinomial distribution with a Dirichlet prior on the
proportion vector to account for the extra variability that is seen in the proportion vector. The Dirichlet
multinomial distribution has been used in a wide range of biological applications including isoform
splicing and microbial communities (Sankaran and Holmes (2018); Holmes et al. (2012)). The isoform
expression for each gene follows a Dirichlet Multinomial distribution with a set of parameters unique
to each gene. SupposeXg is a vector of counts corresponding to the isoform level expression of gene
g estimated via standard quantification methods. Let Ng be fixed and be the overall gene expression
such that
∑Kg
k=1Xgk = Ng, where k = 1, ...Kg corresponds to each isoform for gene g. Let pg be a
probability vector for the expression of isoforms for gene g. Let αg be the Dirichlet parameters for gene
g. We calculate the marginal probability ofXg by obtaining the joint distribution ofXg and pg before
integrating out pg. This distribution is called the Dirichlet Multinomial distribution and the probability



















DRIMSeq uses an empirical Bayes framework to estimate the precision parameters for the Dirichlet
Multinomial distribution by borrowing strength across all genes. This allows for the estimation of
both a common precision and a gene level precision. If the joint distribution of all isoforms follows
8
a Dirichlet Multinomial distribution, then the marginal distribution of each transcript follows a beta-
binomial distribution. Transcript level tests are then conducted using the beta-binomial model with the
parameters that were estimated using the Dirichlet Multinomial distribution.
1.3.3 DEXSeq
DEXSeq utilizes a negative binomial distribution to model the counts per exon. This distribution is
useful in the modeling of count data because it allows for more flexible modeling of the variance. Other
count distributions, such as the Poisson, require that the mean and variance be equal. In many biological
studies, this is too restrictive and thus some type of overdispersion needs to be incorporated. Additionally,
when modeling raw read counts, sequencing depth needs to be appropriately handled to account for the
variability in the number of reads. Let Kijl to be the number of reads for exon l of gene i in sample
j and let sj be the size factor of sample j which accounts for the sequencing depth. Additionally, let
µijl be the expected value of the concentration of reads of gene i, exon l, and sample j and αil be the
dispersion parameter for exon i of gene l. Then Kijl ∼ NB(sjµijl, αil). A negative binomial GLM can





+ βECiρj l. The parameter β
G
i represents the log




fold change in expression of gene i for the experimental condition for sample j. βECiρj l is the effect that
the jth sample’s condition has on the number of reads which align to exon l of gene i. DEXSeq models
the distribution of the per exon counts and thus It was originally targeted for identifying differential exon
usage, but has been also evaluated in the context of transcript usage (Love et al., 2018).
1.3.4 SUPPA2
SUPPA2 estimates the differences in isoform proportions across conditions and between biological
replicates. Changes in the percentage or proportion spliced in (PSI) of splicing events are calculated
between biological replicates and between conditions. The between-replicate estimate of PSI is compared
with the condition estimate of PSI and an empirical distribution of their differences is calculated.
Significance is determined from the tails of this empirical distribution. SUPPA2 offers analyses for both
the splicing events and on a per-transcript basis.
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1.3.5 Genomic Reference Panels
The generation of large genomic databases has led to the discovery of many disease associations and
pathways. A primary focus of the Genotype-Tissue Expression (GTEx) project (The GTEx Consortium
(2017)) is the detection of genetic loci that may act to modulate gene expression levels across different
tissues. This research has also led to the characterization of tissue-specific networks of splicing patterns
(Saha et al. (2018)). The Cancer Genome Atlas (TCGA) (The Cancer Genome Atlas Research Network
et al. (2013)) has collected data for a wide range of cancers and genomic assays to improve ways of
diagnosing, treating, and preventing cancer. Large genomic databases may also serve as reference
panels to gain information about smaller independent datasets and several multi-study methods exist
for this purpose. MultiPLIER (Taroni et al. (2019)), DARTS (Zhang et al. (2019)), and Snaptron
(Wilks et al. (2018)) are just a few examples of these multi-study methods. MultiPLIER utilizes a
transfer learning framework to aid in the identification of rare disease associations with gene expression
in small datasets by borrowing information available in a reference panel. DARTS uses reference
panels to increase power in the identification of differential alternative splicing in small sample datasets
through the implementation of a deep neural network. Snaptron is a tool for querying and subsetting
the visualization of isoform splicing patterns from over 70,000 samples from SRAv1, SRAv2, GTEx,
and TCGA. IsoformSwitchAnalyzeR (Vitting-Seerup and Sandelin (2019)) uses known protein domains
to label isoform switches and to identify downstream functional changes due to differential splicing.
IsoformSwitchAnalyzeR utilizes the results of a differential splicing analysis and existing annotation
databases to characterize the function results of an experiment. Likewise, tappAS (de la Fuente et al.
(2019)) uses annotation databases of functional domains and motifs to provide functional annotation of
differential isoform analyses for a given dataset. Additionally, methods have used GTEx to identify rare
splicing events and for the detection of outliers using either a Beta-Binomial (Mertes et al. (2019)) or
Dirichlet Multinomial distribution (Ferraro et al. (2019)). Genomic reference panels could be used to help
improve inference on splicing patterns from independent experimental datasets. While little work has
been done in this area, there has been some work in the clustering of samples based on isoform splicing.
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1.3.6 Distances on Isoform Proportions
While methods for determining if the isoform proportions are differential across conditions are of
biological interest, there is also interest in unsupervised comparisons of individual samples based on
their isoform splicing patterns. Johnson and Purdom (2017) examined isoform splicing data for the
purposes of clustering samples in an unsupervised setting. They proposed taking a weighted sum of
a per gene distance as a metric of similarity between samples. Let Xijk be the ith sample’s isoform
expression of the kth isoform for gene j. Then the total gene expression is the sum of the expression over
all isoforms Xij =
∑Kj
k=1Xijk. One can then calculate the proportion of the total gene expression of







). One can then define the distance between two samples (i and i′) as a weighted
sum of each gene distance D(i, i′) =
∑p
j=1wjdj(pij , pi′j). Multiple distance metrics were investigated
by Johnson and Purdom including a Squared χ2, Euclidean, Jeffrey’s Divergence, Hellinger, and a
log-likelihood based distance. The authors recommend a Hellinger distance for each gene given by








pi′jk)2 because of its superior performance in simulations and real
datasets. The authors also attempted to estimate gene weights using an L1 penalty to impose sparsity,
but found a large amount variability in the clustering results and poor performance in most simulations.
Gene weights were thus assigned to be constant across all genes.
A distance-based approach is quite effective for the purposes of clustering samples and can also
be used for the comparison of one experimental sample with a collection of samples from a reference
database. Herein, we will refer to the smaller experimental dataset of interest as the “experimental
dataset” and the independent large genomic database as the “reference panel”. If the reference panel has
a predefined discrete grouping of samples, distances can be used to determine which reference group a
sample is most similar to. Distances can be calculated between the sample of interest and all samples
in the reference panel. One could then examine the pairwise distances and identify which reference
group provided a “large” number of samples with a small distance, e.g., a majority vote classifier based
on the k closest samples in the reference panel. However, using this approach for this purpose has
some limitations. A distance-based approach requires that a pairwise distance is calculated between an
experimental sample and every sample in the reference dataset. In some reference panels, the number of
samples can be large (∼10, 000), which creates challenges with computation time as well as the storage
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capacity. Additionally, these comparisons would be performed with only one experimental sample at
a time, and thus there is not a straightforward way to aggregate across experimental samples to make
conclusions about the experiment as a whole. Pairwise distances do not naturally take into account the
biological variability of the reference groups unless a Mahalanobis, or similar type of distance is used.
A reference group could contain an outlying sample that aligns almost perfectly with an experimental
sample. As a result, if conclusions are being made based on the reference sample with the smallest
distance, the results may rely heavily on the presence of outliers. Distances also lack a consistent scale
across datasets with a varying number of genes, which may make it difficult to compare degrees of
similarity of samples to reference panels across various datasets.
Another potential drawback of a distance-based approach for the comparison of samples to a
reference panel is that potentially interesting patterns among genes are not revealed through the analysis.
Examining the pairwise sample distances can give insight into the general similarity of samples based
on splicing patterns, however more investigation must be done to make gene level conclusions. For
example, a sample may splice similarly to only a single reference panel group for gene A, while it may
splice similarly to a number of reference panel groups for gene B. It is desirable to characterize these
gene-specific aspects of the splicing patterns as well as provide an aggregate view of similarity.
Due to these challenges, a probabilistic model may be more appealing, in particular one that
formalizes the relationship of the sample(s) to the information provided by the reference panel. Latent
Dirichlet Allocation (LDA) is a text mining model that has been applied to biological settings in the past
for its ability to identify flexible mixture distributions of latent classes. We considered an extension of
the LDA framework to isoform splicing, and the comparison of a sample to a reference panel.
1.3.7 Topic Modeling - LDA
Topic modeling is a collection of statistical models aimed at discovering latent topics that occur in
a set of written documents. One such model is Latent Dirichlet Allocation (LDA) (Blei et al. (2003)
and Pritchard et al. (2000)). The use of topic modeling is becoming more prevalent in biological
research with applications to the microbiome (Sankaran and Holmes (2018); Holmes et al. (2012)) and in
single cell transposase-accessible chromatin sequencing (scATAC-Seq) (González-Blas et al. (2019)).
Topic modeling for the microbiome allowed for the identification of bacterial communities with similar
expression. Bacterial species may appear in multiple contexts and thus application of LDA allows for
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certain bacterial species to be flexibly modeled as a distribution across the latent species collections.
Topic modeling for scATAC-Seq was used for the identification of cell types, enhancers, and relevant
transcription factors. Another model related to the work presented here is MixDir, a Bayesian model for
high dimensional clustering of samples based on high dimensional categorical data such as surveys and
questionnaires (Ahlmann-Eltze and Yau (2018)). MixDir proposes a generative model similar to LDA,
and employs latent classes to group similar observations, based on their responses to a moderately-sized
number of multiple-choice questions (e.g. < 60 questions). Due to the count nature of isoform splicing
data, the generative model proposed in LDA is a good starting point for constructing a probabilistic
model to characterize the similarity of a set of samples to predefined reference groups using mixtures.
Latent Dirichlet Allocation (LDA) has been proposed as a probabilistic model for text mining as well
as in inferring population structure using genotype data. In the text mining application, LDA examines the
frequencies of words in a large collection of documents to infer latent classes that characterize documents
based on the distribution of word usage. These latent classes are often associated with a genre or topic for
the documents. LDA follows a generative model that can be described per document as follows. First a
probability vector (θ) for the latent topics is generated. Then for each word, a topic (zn) is chosen from
a Multinomial distribution with the previous probability vector (θ). Finally, a word (wn) is randomly
chosen from a Multinomial probability (β) conditioned on the topic (zn). This generative model is fit
using a variational Bayes estimation procedure. The generative model for LDA is outlined below.
1. Choose a latent topic probability vector θ ∼ Dir(α)
2. For each of the N words wn
(a) Choose a topic zn ∼Multinomial(θ)
(b) Choose a word wn ∼Multinomial(z′nβ), a multinomial probability specific to the latent
topic
Using this generative model, the joint likelihood can be calculated as seen in 1.4. Since the only
observed components in the likelihood below are w, it would be desirable to integrate out θ and z but
this would create an intractable distribution. Instead, LDA utilizes variational Bayes inference to estimate
the latent variables.
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Variational Bayes inference involves finding a “candidate” distribution for the full likelihood and
minimizing the distance between the two distributions. Let q(θ,z) be the candidate distribution for
the full log-likelihood. An application of Jensen’s inequality on line 3 of 1.5 allows for the observed
likelihood to be bounded by the difference in the expectation of the full and candidate distributions with
respect to the distributions in the candidate likelihood.



















The difference between the left- and right- hand side of 1.5 corrsponds to the Kullback-Leibler (KL)
divergence between the full and candidate distributions. Thus, maximizing this lower bound, or evidence
lower bound (ELBO), is equivalent to minimizing the KL divergence between the two likelihoods. The
choice of candidate distribution is important for the efficiency and accuracy of the estimation algorithm.
In LDA, the variational distribution is chosen such that all components are independent. θ follows a
Dirichlet distribution with new parameter γ, while zn follows a Multinomial distribution with probability
vector φn. Thus, q(θ,z|γ, φ) = q(θ|γ)
∏N
n=1 q(zn|φn). The lower bound from 1.5 can now be written
as seen in 1.6. This new expression for the lower bound can be written solely in terms of the parameters
γ, φ, α, and β. Parameters are estimated with respect to maximizing this likelihood by iterating between
estimating the variational and model parameters.
L(γ, φ, α, β) = Eq[log p(θ|α)] + Eq[log p(z|θ)] + Eq[log p(w|z, β)]
− Eq[log q(θ)]− Eq[log q(z)]
(1.6)
In an analysis of 16,000 articles from the Associated Press, LDA was able to identify latent classes
which loosely resembled the arts, budget, children, and education. Words such as “million”, “tax”, and
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“program” were more often seen in the latent class associated with budget while words such as “school”,
“students”, and “teachers” were most commonly seen in the latent class associated with education. Topic
modeling has become more common in biological applications and here we propose LDA as a framework
to relate isoform splicing patterns to a reference panel.
1.3.8 Summary
Extensive work has been done to characterize isoform splicing patterns. The majority of this work
is in the form of identifying genes exhibiting DTU and DRIMSeq, DEXSeq, and SUPPA2 are three of
a large number of available methods. There is also an extensive literature for utilizing large genomic
databases to gain information about smaller datasets. However, we are not aware of any work comparing
isoform splicing patterns from an independent dataset with those in a reference panel. Probabilistic
models constructed for text mining, such as LDA, provide a good starting point for creating such a model
which relates isoform splicing patterns in an independent experimental dataset to those in a reference
panel.
1.4 Sample Quality Weighting
1.4.1 Weighting Methods
Several statistical methods have been developed to improve method performance by down-weighting
low quality samples. One such method, Voom (Law et al. (2014)), down-weights observations with low
counts for use in linear modeling. Voom fits a LOESS curve through the mean-variance relationship of
the log counts per million. (Liu et al., 2015) proposed an extension of this methodology by combining
the voom weights with sample specific weights to increase power in RNA-seq analyses. Sample and
observational level heterogeneity is modeled using a log-linear variance model and the sample specific
weights are calculated as the inverse of the estimated sample variance factors. Weighting samples has also
been used to dampen the effect of outliers within a Negative Binomial GLM of a differential expression
analysis (Chen et al. (2016)). Here, weights are calculated using a Huber function on the Pearson Residual
obtained from the previous iteration of the NB-GLM. The weights are then provided back into the model
and repeated until convergence.
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(Smallwood et al., 2014) implemented observation weighting in the analysis of single-cell genome-
wide bisulfite sequencing data to identify DNA methylation at CpG sites. The methylated and un-
methylated counts are aggregated within sliding positional windows and then modeled using a binomial
distribution with a beta prior on the methylation rate. Each sample and window receives a weight equal
to the inverse estimated variance of the methylation rate. This observation-level weighting technique was
employed later in an integrative study of transcriptional and epigenetic variation in mouse embryonic stem
cells (Angermueller et al. (2016)). Observation-level weights at CpG sites were used to find associations
between methylated distal regulatory elements and the transcription of several important pluripotency
factors.
While the above methods weight samples based on the observed data, they do not make use of any
external covariates that might aid in defining the weights. Several other methods have utilized external
covariates in deriving feature-level weights in the context of multiple hypothesis testing. In genomics
studies, there are often thousands or millions of statistical tests, and so it is common to apply some form
of multiple test correction to avoid inflation of type I errors. These corrections inherently involve a loss
in power compared to the marginal, per-feature tests, and thus several methods have been developed
to appropriately weight the statistical tests to improve overall power. (Roeder and Wasserman, 2009)
provide an in depth look at several methods that perform weighted hypothesis testing in Genome-Wide
Association Studies (GWAS). They characterized hypothesis weighting methods in to two categories: 1)
external weighting based on prior scientific information for specific hypotheses and 2) data-driven weights.
Additionally, (Ignatiadis et al., 2016) established a data-driven approach called Independent Hypothesis
Weighting (IHW) that uses an external covariate to identify the optimal weights. The hypothesis tests
are grouped into bins based on the value of the external covariate and weights are assigned to each bin.
IHW was benchmarked along with other methods that control false discovery rates (FDR) and was found
to have lower FDR and did not underperform when the covariate was uninformative (Korthauer et al.
(2019) ). While covariate-based weighting was found to have improved performance within the multiple
hypothesis testing setting, in Chapter 4 we will consider covariate-based sample weighting in the context
of integrative analysis of multiple assays.
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1.4.2 Weighted CCA
In Section 1.1.2, Sparse CCA was introduced for the analysis of two data types. An extension to
Sparse CCA was developed with the addition of sparse sample weights called Sparse Weighted CCA
(SWCCA, (Min et al., 2018)). In this formulation, sample weights are added to the objective function
and a penalty is imposed on the weights such that larger weights indicate sample inclusion and smaller
weights suggest the impact of the objective should be reduced. The objective function for this method













The above objective function is particularly convenient in that there exists closed form solutions for
the updates of β1, β2 and the sample weight vector, w, given fixed estimates of the other two parameters,
thus avoiding the need for an iterative estimation step within the update of each variable. The added
sparsity of pushing sample weights to zero may be convenient for datasets in which strong sample
heterogeneity exists, and certain samples contribute essentially nothing to the shared variation across
assay, however the objective function may overly favor the entire removal of samples. The selection of
a tuning parameter may play an important role to avoid such excessive removal of samples, but tuning
parameter selection is not discussed by (Min et al., 2018). The SWCCA framework therefore provides
motivation for our extension of Sparse CCA to accommodate covariate-based sample weighting as will
be seen in Chapter 4.
1.4.3 Summary
Several methods utilize weights to improve method performance. These methods seek to address this
problem in one or more of three ways: 1) using prior scientific information, 2) to optimize a specified
objective, or 3) using external covariates to learn the weights. In terms of analyzing multiple data
assays jointly to identify shared variability, only Sparse Weighted CCA and the analyses performed by
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(Angermueller et al., 2016) looked at incorporating weights into the analysis. Learning weights can be
improved by including external covariates, which we will address in Chapter 4.
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CHAPTER 2: MOVIE - MULTI-OMICS VISUALIZATION OF ESTIMATED CONTRIBUTIONS
2.1 Framework for Evaluation of Methods
The goal of this chapter is to identify the extent of overfitting and the consistency of multi-omics
methods. The work for this chapter is also available in (McCabe et al., 2019). We do not attempt to
simulate multi-omics datasets, as it is extremely difficult to propose realistic patterns of covariance
among numerous multi-omics assays. Instead, we aim to evaluate method performance by examining
the contribution of each sample in each data type towards the common variation space and by utilizing
a k-fold cross-validation to assess stability and potential overfitting. All of the published unsupervised
multi-omic methods examined here performed well on large sample-size datasets, but some displayed
some inconsistency on smaller sample-size datasets. We provide an R package for reproducing the results
here and detailed Rmarkdown vignettes demonstrating software usage. We suggest that researchers in
the burgeoning field of multi-omics consider the evaluation framework presented here, which leverages
the inherent properties of multi-omics datasets, for assessing newly proposed methods or refinements of
existing methods.
We chose to evaluate three published unsupervised multi-omics methods, Sparse mCCA (Witten
and Tibshirani, 2009), AJIVE (Feng et al., 2018), and MOFA (Argelaguet et al., 2018), as well as
a simple approach for applying classical CCA to high dimensional data by first applying dimension
reduction, discussed below. These three published methods were chosen for their ability to take three
or more high dimensional matrices as input, corresponding to multiple data types measured on the
same individuals, and to extract feature weights per data type, described in more detail in the following
section in our framework for the evaluation of methods. In addition, methods were chosen either for
having a high citation count (hundreds of papers citing the publications for Sparse mCCA and AJIVE, an
earlier algorithm for which AJIVE is an improvement/refinement), or for evidence of recent and ongoing
development and community interest (MOFA with dozens of citations since its publication in 2018, and
detailed documentation and tutorials). While numerous additional methods are available for unsupervised
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multi-omics integration and analysis, we attempted to choose a small number that represent distinct
geometric decompositions or statistical models capturing common variation across samples for multiple
types of data.
2.1.1 Contributions
Each of the methods of interest provide sets of weights corresponding to the importance of each
feature in each data type. The larger the absolute value of the weight, the more the corresponding feature
contributes to the common variation. Instead of examining results in the feature space, we instead look
on the sample space and observe relationships across data types and samples. This is accomplished
by constructing what we call a contribution, which is calculated by multiplying the estimated weights
and the data to obtain an individual contribution per subject. Let β̂i be the pi by 1 dimensional vector
corresponding to the estimated weights for data type i, and let Xi be the pi by n matrix corresponding
to data type i. The contribution is then calculated as β̂′iXi. Contributions can be calculated for any
multi-omics method, as long as the output provides a list of weights. We will demonstrate how this
is done in PC-CCA, Sparse mCCA, AJIVE, and MOFA. Because both PC-CCA and Sparse mCCA
are modifications of Canonical Correlation Analysis (CCA), the calculation of the contributions are
trivial. The weights β̂i in this case correspond to the solution for each data type, and a simple matrix
multiplication can be performed to calculate the contributions. For AJIVE and MOFA, the contributions
are not difficult to calculate; however, because these methods identify a multi-dimensional solution, we
only focus on the weights for one factor (Figure 2.2). In AJIVE, this corresponds to the first column of
the loadings matrix of the joint space, and for MOFA, this corresponds to the weights for the top factor.
In the MOFA analysis, we restrict the method to fit only one factor.
Once contributions are found for each data type, they can be plotted against the contributions
of another data type to visualize the relationships identified by the multi-omics method of interest.
Additionally, samples that fall off of the diagonal in a contribution plot may be biologically meaningful
outliers, or technical outliers for one of the assays. This plot is termed the contribution plot, and we can
identify method overfitting using a cross-validation analysis.
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Figure 2.2: Each method shown in the figure generates a set of weights for each data type. Our analysis
only considers the first set of weights to avoid issues related to a potentially complex set of mappings of
factors across data splits.
2.1.2 Cross-validation
The unsupervised nature of the multi-omic methods makes it difficult to determine whether a method
is overfitting or identifying a true biological relationship. By omitting a subset of the samples from the
analysis and predicting their contributions from each data type in the training set, we can discern whether
the relationships from the full analysis suffer from overfitting or provide unstable results. Our analysis
pipeline is shown in Figure 2.3. We chose to divide the data into training and test sets of approximately
80% / 20% of the total samples. Using the 80% training set, analyses were done for each method, and
corresponding weights were generated for each data type. Contributions were calculated for the test set
by multiplying the weights derived from the training set by the test set data in the manner appropriate to
each method, as defined above. Critically, our cross-validation loop used for evaluation of methods takes
place outside of any permutation or cross-validation that a method may use during training or fitting of
its model parameters, such as the calculation of feature weights for each data type.
The results of the methods may not be unique, which can lead to slight alterations in scaling and
sign. Due to this, the results across folds may identify the same biological process, but provide results of
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different magnitudes. To account for this, we scale and change the sign of the cross-validated contributions
to ensure that they are positively correlated with the results from the full analysis. This procedure is
performed separately for each fold. The sign is flipped if the correlation between the cross-validated and
full-analysis contributions is negative, while scaling is achieved by subtracting the mean and dividing it
by either the standard deviation or the median absolute deviation. If the contributions are not unimodal or
contain outliers, we recommend using the median absolute deviation for scaling.
To avoid difficulties in aligning weights across folds, in our evaluation we only consider the set of
weights corresponding to the first factor. In MOFA, factors are arbitrarily labelled and thus no formal
ordering is defined for the “first” or “second” factor. Repeating the analysis will yield a different labelling
scheme for each factor while factors are still describing the same biological process. This necessitates
the alignment of factors across multiple folds and creates a computational challenge. For sparse mCCA
and MOFA, the first set of weights or first factor typically yields the strongest pair-wise correlations.
As more sets of weights are estimated, the correlations typically decrease (see Fig 2b in (Argelaguet
et al., 2018)). Lower factors may be more susceptible to fluctuations, such as sampling variability in the
samples chosen for the training set.
After the contributions are appropriately scaled, contribution plots can be constructed for each
pair-wise combination of the assays in the test set. We will refer to these plots as the cross-validation
(CV) contribution plots and the contribution plots from the full analysis as the full contribution plots.
By examining the change in correlations between the CV contribution plots and the full contribution
plots for each pair-wise data type pair, we may observe the degree to which each method suffers from
overfitting. The full contribution plots reflect the typical results that a user would observe when running a
method on their entire dataset, while the CV contribution plots reveal any issues with the generalization
of feature weights for new data, in that we observe the correlations obtained on all samples in the dataset
when those samples are not used for training. It is important to note that because the identified factor
may only be a small portion of the entire solution, the correlation of the contribution plot should not
be compared across methods, but rather within one method by comparing the correlation in the full
analysis to the correlation in the cross-validated analysis. Methods like AJIVE and MOFA identify a
multi-dimensional solution, and thus, a low correlation in the contribution plot may not indicate that the
method is performing poorly, but rather that the top factor captures a low correlation between the two
data types of interest. Figure 2.4 provides examples of good and poor results for the contribution plot
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Figure 2.3: Pipeline for cross-validation analysis. Training Data: Dataset is subset to 80% of the original
data and will be used to train the model. Multi-omics Methods: The training data are analyzed using the
specified method. Output: Weights are output from the multi-omics methods. Test Data: The remaining
20% of the original data are used as test data and multiplied by the subsequent weights. Contributions:
The result of multiplying the output weights by the test set data. Each sample in the test data yields one
number that represents the contribution per data type.
generated using artificial data. Figure 2.4a shows a strong correlation in both the full and CV contribution
plots, indicating that the method is not overfitting and that the two data types are related. Figure 2.4b
shows no correlation in the full and CV contribution plots, which also indicates that the method is not
overfitting, but rather, that the two data types are not related. Figure 2.4c shows a strong correlation in the
full contribution plot and no correlation in the CV contribution plot, thus demonstrating that the method
is overfitting on the data and that there does not appear to be a relationship between these two data types.
We also generate overfitting plots, which plots lines connecting the pair-wise correlations of the full and
cross-validated contribution plots to provide a useful overview of the change in correlation between the
full and CV analysis for all pairs of assays. We also plot contributions from the cross-validation analysis
against contributions from the full analysis within each data type. We call these the comparison plots,
and a strong linear correlation indicates method consistency.
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2.1.3 Multi-omics Datasets
Data from The Cancer Genome Atlas (TCGA) (Wong et al., 2019) (The Cancer Genome Atlas
Research Network et al., 2013) was used to evaluate method performance for Sparse mCCA, AJIVE,
and MOFA. We applied these three methods to 558 breast cancer samples using Copy Number Variation
(CNV), RNA expression, and micro RNA expression. CNV was summarized for 216 segments; RNA
expression was measured for 12,434 genes; and miRNA expression was measured for 305 miRNAs.
Five folds were selected for the analysis, and fold membership was fully randomized. Contribution
and comparison plots were generated for each data type to evaluate the degree of overfitting and the
consistency of the results.
Data from Li, et al (2016) was used as a second validation data set. This collection of datasets
contained fewer samples and thus was used to examine stability of methods with smaller sample sizes.
RNA expression, DNase, and protein expression were collected for lymphoblastoid cell lines from
Yoruban individuals. DNase was measured for 699,906 peaks; RNA expression was measured for 13,967
genes; and protein expression was measured for 4,375 proteins for 53 samples.
To demonstrate the ability of our framework to identify overfitting, we analyzed datasets with no
relationship across assays, referred to as null datasets, using PC-CCA, Sparse mCCA, AJIVE, and MOFA.
Permuted null datasets were generated by permuting the samples for each data type in the TCGA breast
cancer data. Because PC-CCA can only accommodate two data types, we used only RNA and miRNA for
this analysis. Five folds were selected for the analysis, with the fold membership being fully randomized.
For all datasets, contribution plots, comparison plots, and overfitting plots were generated to evaluate
method performance.
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Figure 2.4: The figure provides hypothetical scenarios for the contribution plot, generated using artificial
data. a. A strong correlation in both the full and CV plots, indicating that the method accurately fits the
data and that the two data types are linearly related. b. A null correlation in both the full and CV plots,
indicating that the method did not overfit and that the two data types are not related in terms of this factor.
c. A strong linear relationship in the full plot and a null relationship in the CV plots, indicating that the
method overfit and that the two data types are not associated with the top factor.
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Figure 2.5: Overfitting plot: Plots of the pair-wise correlations identified in the full and CV contribution
plots for each method. The left column (plots a-c) corresponds to the large-sample analysis (n=558;
TCGA breast cancer), while the right column (plots d-f) corresponds to the small-sample size analysis
(n=53; Li, et al 2016) . Rows correspond to AJIVE, Sparse mCCA, and MOFA, respectively. Flat lines
indicate non-overfitting methods, while lines with a negative slope indicate a large change in the results
for the full and CV plots.
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2.2 Evaluation of Methods
We applied our evaluation framework to datasets with both large (TCGA breast cancer) and small (Li
et al) sample sizes, as well as a permuted null dataset. Sparse mCCA, AJIVE, and MOFA all demonstrate
consistency and a lack of overfitting in the large-sample size analysis. The overfitting plots for the
large-sample size analysis (Figure 2.5 a-c) have near zero slopes, indicating that the relationships found
in the training set generalize to the held-out set. The difference in the magnitude of the correlations
across methods does not indicate a lack of overfitting, but rather that the top factor indicated a strong or
weak relationship between the specified data types. This artifact is not necessarily a limitation of the
method, but rather might be explained by the fact that we are considering only the first set of weights in
our analysis. Side-by-side contribution plots (Supplementary Figures A.17 - A.25 ) also demonstrate a
lack of overfitting and confirm that there are no sample outliers that are overly influencing the results.
Comparison plots (Supplementary Figures A.26- A.28) show that the contributions for the CV analysis
and full analysis are similar, indicating overall method consistency. AJIVE was observed to have reduced
pair-wise correlations for contributions including the CNV assay, and this result persisted after attempting
with a higher pre-specified rank (Supplementary Figure A.29). Overall, for the large-sample size analysis,
we found that Sparse mCCA and MOFA did not overfit and found large pair-wise correlations between
contributions from all assays. AJIVE also showed a lack of overfitting, however a large pair-wise
correlation was only found between RNA and miRNA.
We further investigated the contributions for AJIVE, Sparse mCCA, and MOFA. Contributions from
Sparse mCCA are highly correlated (r > 0.97, Pearson correlation coefficient) with MOFA across all
data types. AJIVE contributions have strong negative correlations with both Sparse mCCA (r = −0.91)
and MOFA (r = −0.92) for mRNA (noting that the sign here is arbitrary), while exhibiting a moderate
negative correlation in miRNA (r ≈ −0.77). AJIVE contributions for CNV are not correlated with Sparse
mCCA (r = −0.03) or MOFA (r = 0.05) (Supplementary Figures A.30-A.32). mRNA contributions for
all methods were found to be bimodal and highly correlated with the expression of the estrogen receptor
1 (ESR1) gene (Supplementary Figure A.33). Previous studies have found that the expression of the
ESR1 gene is amplified in a subset of breast cancers, providing some biological validation for the top
contribution – estimated without any prior information about ESR1 gene expression – for all methods
run on this dataset (Holst et al., 2007).
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Alternatively, in the small-sample size analysis, Sparse mCCA and MOFA appear to overfit in the
full analysis, while AJIVE does not overfit. Plot 2.5d shows a lack of overfitting with AJIVE in the
small-sample analysis, while plots 2.5e and 2.5f show a consistent drop in the correlation for the CV
analysis. Thus, sparse mCCA and MOFA are able to identify strong linear relationships in the full
analysis, but the correlations are substantially reduced in the CV analysis. This may reflect a reduced
ability for consistent detection of top factors for small-sample datasets. Side-by-side contribution plots
(Supplementary Figures A.34 - A.42) show more clearly a decrease in correlation with Sparse mCCA and
MOFA, but not with AJIVE, which maintains a relatively weak correlation in both analyses. Comparison
plots (Supplementary Figures A.43 - A.45) show less consistency than in the large-sample analysis.
We assessed the degree to which the results were robust when varying the number of folds. Sparse
mCCA was used to analyze the small-sample size dataset using both 3 and 10 folds. The 3 fold analysis
yielded small training set sizes, which led to poor prediction for the test set samples (Supplementary
Figure A.46). Alternatively, in the 10 fold analysis, small test set sizes made contribution scaling difficult,
which also led to reduced correlation of the cross-validated contributions with the full set contributions
(Supplementary Figure A.47). Additionally, many methods have extensive run times and thus conducting
an analysis with many folds can create a prohibitive computational burden.
Analyses for the permuted null dataset showed that PC-CCA using 100 PCs per data type identifies a
strong relationship between miRNA and RNA when no relationship exists (Figure 2.6 a). Sparse mCCA
correctly identifies no relationship (Figure 2.6 b) in the full analysis; AJIVE and MOFA also identify
no relationship (Supplementary Figures A.48 - A.49). These plots show the ability of our framework to
identify overfitting, as well as the ability of Sparse mCCA, AJIVE, and MOFA to not overfit the null
dataset.
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Figure 2.6: Side-By-Side contribution plots for a) PC-CCA with 100 PCs and b) Sparse mCCA with the
null dataset: Left panels show the contribution plots from the full analysis, while right panels show the
contribution plots for the CV analysis. Pair-wise correlations are reported on the figure.
2.3 Discussion
In this paper, we have proposed a framework and approach for the evaluation of unsupervised
multi-omics methods. Sparse mCCA, AJIVE, MOFA, and PC-CCA were compared based on consistency
and the degree of overfitting in one large-sample size dataset, one small-sample size dataset and one
permuted null dataset. All methods performed well with the large-sample dataset, with AJIVE somewhat
underperforming by failing to detect a contribution from CNV to the top factor, which other methods
detected and which had stable correlation in cross-validated contributions. However, both Sparse mCCA
and MOFA showed some evidence of either overfitting or lack of consistency with the small-sample
dataset. PC-CCA overfit the null dataset, while the other methods accurately identified a null relationship.
Previous work (Pucher et al., 2019) looked at the sensitivity and specificity of methods using simulated
data. In contrast, our framework examines the extent of overfitting and does not make any simulation
assumptions.
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There are now dozens of methods for unsupervised multi-omics data analysis, and the list continues
to grow. Other multi-omics approaches that we did not compare here use re-formulations of partial least
squares (PLS) (Lê Cao et al., 2009) , or co-inertia analysis (CIA) (Meng et al., 2014), and often make use
of lasso penalty or sparse thresholding to induce sparsity on feature weights.(Rohart et al., 2017)
Future work may include investigation into the alignment of weights across folds and replications
and how to incorporate more than one set of weights. Argelaguet et al (2019) (Argelaguet et al., 2019)
propose comparing the Pearson correlation coefficient between every pair of factors as a way to address
these concerns. Additionally, classical CCA could be used to perform matching of factors across folds or
replicate runs, by running CCA on every pair of contributions. We did not evaluate the sensitivity and
specificity of the methods we tested, as they are designed to describe variation, rather than classification,
of samples. A separate analysis similar to Pucher et al (2018) (Pucher et al., 2019) would be needed to
evaluate AJIVE and MOFA on the claims of accuracy. Here we examined the biological meaningfulness
of the top factor found in the TCGA breast cancer dataset by plotting the mRNA contributions against
expression of estrogen receptor 1, for which we have from literature some external support of its
relevance as a primary axis of co-variation of molecular profiles of breast tumors. In general, downstream
assessment of the biological meaningfulness of a factor can be achieved through gene set analysis, by
defining the observed gene set as the non-zero or top weighted genes from the gene expression weights
estimated by the multi-omics methods. The MOFA R package includes a function for performing this
type of “Feature Set Enrichment Analysis”. For non-gene expression features, non-zero or top weights
for features can be examined with respect to their co-localization with weights from other data types
on the genome, or with various publicly available genomic tracks such as cell-type specific regulatory
regions (ENCODE Project Consortium, 2012)(Roadmap Epigenomics Consortium, 2015).
We provide an R package called MOVIE (Multi-Omics VIsualization of Estimated contributions)
and documentation to assist with the comparison of future methods and datasets using our framework.
Package source code is publicly available: https://github.com/mccabes292/movie.
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CHAPTER 3: ACTOR - A LATENT DIRICHLET MODEL TO COMPARE EXPRESSED ISO-
FORM PROPORTIONS TO A REFERENCE PANEL
The relative proportion of RNA isoforms expressed for a given gene has been associated with
disease states in cancer, retinal diseases, and neurological disorders. At the gene level, expression
can be functionally characterized by known gene sets. However, there is less annotation data at the
transcript level and there are fewer statistical methods designed specifically for recognizing characteristic
splicing patterns. An alternative approach would be to characterize the splicing patterns in a sample,
or set of samples, by comparing the patterns to those seen in a large reference panel. While some
methodological comparisons have been made in the area of clustering samples based on isoform splicing,
less development has been made in comparing experimental data to a reference panel. Leveraging large
public datasets produced by genomic consortia as a reference, one can compare splicing patterns in a
dataset of interest with those of a reference panel in which samples are divided into distinct groups (tissue
of origin, disease status, etc.). We propose ACTOR, A latent Dirichlet model to Compare expressed
isoform proportions TO a Reference panel, to relate isoform splicing patterns in an experimental dataset
to an independent reference panel composed of discrete sample groupings. We provide gene level
interpretations of the relatedness across experimental samples and provide an improvement to standard
distance-based approaches. ACTOR was validated using data from the Genotype-Tissue Expression
project (GTEx) and accurately identified genes and gene classes for which isoform splicing was similar
across tissues.
3.1 ACTOR
We first model the estimated isoform expression of each gene in each reference group in our reference
panel using the Dirichlet Multinomial distribution. Assuming that for each gene (g) all samples within
a specific reference group (s) are i.i.d. Dirichlet Multinomial, we calculate the maximum likelihood
estimates for the distribution parameters, αgs. These estimates can be calculated for all gene and
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reference group combinations, which reduces the reference panel to a more manageable size. For a
sample (j) in the experimental dataset, we calculate a per gene (g) likelihood conditional on the parameter
estimates coming from a specific reference panel group (s) as p(Xgj |αgs). Using these likelihoods, we
wish to identify latent groupings of genes that are spliced in a similar manner to our reference groups.
Identifying these gene classes can be a challenging task, and topic modeling through the use of Latent
Dirichlet Allocation (LDA) can provide a means to accomplishing this task. Figure 3.7 provides a
visualization of our method and Supplementary Table B.5 provides a table of all notation for this model.
Figure 3.7: ACTOR uses precomputed Dirichlet parameters for each reference group to identify which
reference group a set of experimental samples is most similar to based on isoform splicing patterns. The
curves represent the Dirichlet distribution for each reference group. ‘X’ corresponds to an experimental
sample. For visual simplicity, a one-dimensional simplex is shown here.
Expanding on the LDA framework and incorporating the pre-calculated parameter estimates for the
Dirichlet Multinomial distribution, we construct a generative model to identify the mixture of reference
panel groups found in the isoform splicing of an experimental dataset. Our framework is aligned with the
LDA framework as follows: samples are documents, reference groups are topics, and genes are words.
32
Additionally, we add a second latent component to identify sets of genes, which we call gene classes, that
have similar reference group distributions. Dirichlet Multinomial estimates for each reference group in
our reference panel are pre-calculated, so while the reference group assigned to a gene in our experimental
dataset is a latent variable, the groups themselves are not latent, nor are the parameters describing the
distribution of isoform proportions for a given group. In contrast, the topics in the text-mining LDA
formulation are latent, and discovered during model fitting, while the gene classes are latent in our model.
This reference group assignment within the LDA model makes use of the likelihood conditional on the
reference group estimates.
As mentioned earlier, it is also informative to identify classes of genes that align to the groups in the
reference panel similarly. A sample could splice similarly to the reference groups across one collection of
genes, while splicing similarly to a different set of reference groups in another collection of genes. The
splicing could also be characterized as being unique to one reference group or as a mixture across multiple
groups. We will use the term “gene class” to indicate a collection of genes in the experimental samples
that have a similar relation to the reference groups. All genes within the same class have a common
probability vector corresponding to the reference group from which they are generated. Supplementary
Figure B.50 gives a toy example, with five reference panel groups and four gene classes. Three of the
gene classes correspond to sets of genes that are all spliced similarly to one specific reference group.
Gene class 1 aligns with reference group 1, gene class 2 aligns with reference group 2, and gene class
4 aligns with reference group 5. We also see that there could be situations in which genes are spliced
similarly to two different reference groups. Gene class 3 is shown to be equally similar to reference
groups 3 and 4. Therefore, we aim to estimate both reference group and gene class membership using a
generative probabilistic model in a manner similar to LDA. The user prespecifies the number of gene
classes the model will try to fit. As will be seen in the results, an overestimate of the number of classes
will result in the model creating empty gene classes for those that are not needed.
The task addressed by our proposed model is related but nevertheless distinct from the task addressed
by MixDir (Ahlmann-Eltze and Yau (2018)) in a number of aspects: while MixDir could be used to
cluster thousands of genes (MixDir’s observations) based on their splicing across a moderately-sized
number of samples (MixDir’s questions/features), here we are interested in grouping genes based on
splicing similarity in a set of samples, which are compared to a reference panel. There are also two
relevant datasets for our task, though we precompute distributional parameters for one of them, as
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opposed to only one set of relevant samples. In addition, the reference panel in our setting has known
group structure (e.g. samples belonging to tissues). (Dey et al., 2017) also looked at identifying RNA-seq
structure using latent memberships, however this is also distinct from our approach as they model the
counts as coming from a Multinomial distribution with a different proportion parameter per sample rather
than utilizing a Dirichlet distribution to model the extra variability.
Figure 3.8: Graphical model representation of our proposed framework. Figure a) corresponds to the full
model while Figure b) corresponds to the variational distribution.
ACTOR is a hierarchical latent class model with the first level of latent classes being informed by
the reference panel. The first step of the generative model is to generate a probability vector (γ) of length
C (number of gene classes) for the gene class assignment from a Dirichlet distribution with unknown
parameter ω of length C. This probability vector is common for all genes. For each gene class (l), a
probability vector of length T (number of reference groups) is drawn for the reference group assignment
(θl) from a Dirichlet distribution with unknown parameter β. β is of length T and is common for all
gene classes. For each gene, a gene class (cg) is drawn from a Multinomial distribution with parameter
γ, which was generated in the first step. Then for each gene, a reference group (tg) is drawn from
the Multinomial distribution using the reference group probability vector θl that corresponds with the
selected gene class (cg). In the formulation below, Θ = (θ1, ...,θC)′ is a T x C matrix and cg is a vector
of length C filled with zeros in every entry except for a 1 in the position of the gene class assignment.
If cg assigns a gene to gene class l, then c′gΘ will return the probability vector for gene class l (θl).
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Finally, isoform expression is generated per sample (j) using a Dirichlet Multinomial with parameters
(αgs) which are the Dirichlet Multinomial parameters from the reference panel that correspond to the
reference group selected by tg as drawn earlier. Similarly to cg, tg is a vector of length T with a 1 in the
position of the selected reference group and 0 everywhere else. Likewise, we let Ag = (αg1, ...,αgT )′
be a T x Ig matrix where Ig is the number of isoforms for gene g. Then t′gAg = αgs if tg assigns
a gene to reference group s. Here the Dirichlet Multinomial distribution is written as a multinomial
distribution with a Dirichlet prior on the probability vector pgj , where pgj is a vector of length equal
to the number of isoforms for gene g (Ig). It will be seen later that pgj will not be necessary to the
model and will be integrated out. Also observe that in this model the overall gene expression (Ngj) is
considered to be known and fixed. Since there is only interest in observing alignment based on isoform
splicing, the generating process for gene expression is not of concern and focus is solely on how the
isoform expression is allocated. The generative model is described below and a graphical representation
of the model is in Figure 3.8a.
Select gene class probability vector γ ∼ Dir(ω)
For each Gene Class (l)
Select reference group probability vector θl ∼ Dir(β)
For each Gene (g)
Select Gene Class: cg ∼Mult(γ)
Select Reference Group: tg ∼Mult(c′gΘ)
For Each Sample(j):
Select Iso Prob for Gene g: pgj ∼ Dirichlet(t′gAg)
Select Iso Expr: Xgj ∼Mult(Ngj ,pgj)
Ngj - gene expression for gene g of samples j (assumed known)
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3.2 Variational Bayes Estimation and Implementation
To estimate the latent parameters (the reference group t, the gene class c, the reference group
probabilities per gene class Θ, and the gene class probabilities γ), we implement a variational Bayesian
approach in the same manner as LDA, but accounting for our added structure of gene classes. First, we
calculate the full joint likelihood of our model by multiplying the conditional probability distributions
as shown in Equation B.16. We can integrate out p to get the Dirichlet Multinomial distribution which
models the isoform expression for each biological sample. This replaces p(Xgj |pgj)p(pgj |tg) with
p(Xgj |tg) in our joint likelihood (Equation B.16).



























Our hope is to find p(Θ, t, c|X,β, γ); however, this requires the calculation of p(X|β), which is
intractable. We instead look to find a “candidate” distribution for our full likelihood and try to estimate the
parameters of this distribution which minimizes the difference between the candidate and full likelihoods.
This procedure is known as variational inference (Jordan et al. (1999)) and the full derivation for this can
be seen in Supplementary Methods B.2.1.
The candidate distribution must be carefully chosen so that it accurately depicts the full joint like-
lihood. This is typically handled by removing the dependence across latent variables, but maintaining
the distribution proposed for each variable. We set our candidate distributions for the reference group
probability vector specific to each gene class (θl) to be Dirichlet with a different parameter per gene class
(ηl). The reference group membership for a given gene (tg) is modeled as a Multinomial distribution
with a separate probability vector per gene (φg). The gene class membership for a given gene (cg) is
modeled by a Multinomial distribution with a separate probability vector per gene (λg). Finally, the
probability vector for gene class membership (γ) is modeled by the Dirichlet distribution (ρ). These
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random variables are all assumed to be independent. A diagram of these distributions is shown in Figure













With a full joint likelihood and a candidate likelihood, the variational lower bound can be con-
structed by taking the difference in the expectation of both distributions (Eq[log(p(X,Θ, t, c|β, γ))]−
Eq[log(q(Θ, t, c))]). The expectation is taken with respect to the candidate distributions, which will
remove all unobserved random variables from our estimating equation. The final result gives an equation
dependent on φ,η,λ, ρ, β, and ω and is often called the evidence lower bound (ELBO). Equation







Eq [log p(Xgj |tg)] +
G∑
g=1

















Eq [log q(cg|λg)]− Eq [log q(γ)]
(3.10)
We now maximize the variational lower bound given in equation 3.10. Standard procedures for
maximizing a multivariable distribution apply, and derivatives are calculated with respect to each variable
in question. See Supplementary Methods B.2.2 - B.2.6 for a complete derivation of the estimates that
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maximize the variational lower bound. The resulting derivations give closed form solutions for φ,λ, η,






































ACTOR and its estimation procedure as described above is implemented in the R package actor.
To summarize its usage, actor takes as input the isoform-level estimated counts for all samples in
an experimental dataset and utilizes the pre-computed Dirichlet estimates for a large, tissue-specific
RNA-seq expression dataset (the GTEx project dataset, described below) as a reference panel stored
internally in the R package. actor provides posterior estimates for all latent variables in the model as
well as any additional parameters needed for fitting the model. Graphical visualizations of the posterior
estimates are also available. In particular, posterior estimates of tg, the T dimensional vectors for gene
level membership to the reference group (φg), posterior estimates of cg, the C dimensional vectors for
gene level membership to the gene class (λg), and posterior estimates of θl, the T dimensional vectors
of gene class estimates (ηl) are of most interest. Detailed package vignettes provide guidance on the
calculation and interpretation of these results.
3.3 Results
3.3.1 GTEx and Data Processing
We utilized data from version 7 of the Genotype-Tissue Expression project (GTEx) as a reference
panel. The GTEx consortium was established to study tissue-specific gene expression and identify
expression quantitative trait loci (eQTL) across tissues. The dataset consists of gene expression data
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from 53 tissue types for over 15,000 samples collected from non-diseased individuals post-mortem.
GTEx provides a natural fit for our proposed model as the gene expression data is publicly available
and the discrete groupings of tissues define the reference groups. Small sample sizes could create
unreliable parameter estimates and thus tissues with fewer than 50 samples were removed from the
analysis: samples from the bladder (n=11), endocervix (n=6), ectocervix (n=5), fallopian tube (n=7), and
kidney (n=45) were excluded. Gene filtering and parameter estimates were performed separately for
each tissue. Genes that did not have at least 70% of samples with a gene count greater than 10 were not
estimated and were considered not expressed for that tissue. Additionally, we considered the number of
isoforms per gene as a potential filter. Increasing uncertainty in estimation of isoform expression levels
and higher error rate in differential testing has been observed with increasing number of isoforms for
a gene (Leng et al. (2013); Soneson et al. (2016)), so we restricted our analyses to genes with five or
fewer annotated isoforms. For the genes that passed the isoform filtering (8718 genes), tissue specific
maximum likelihood parameter estimates were calculated for the Dirichlet-Multinomial distribution using
the R package DirichletMultinomial (Morgan (2019)). Maximum likelihood estimates for the precision
parameter of the Dirichlet Multinomial can yield very large values that can lead to small likelihoods
for experimental samples that are only slightly off from the spike. To combat this, we set the precision
parameter to 50 if the calculated precision estimate was over 50.
3.3.2 Simulated Data
To demonstrate ACTOR’s model fitting and to compare with a distance-based approach, we simulated
data from five GTEx tissues to demonstrate the fit of our model. Cerebellum, liver, spinal cord, pancreas,
and the tibial nerve have been known to have the most distinct alternative splicing patterns (Yeo et al.
(2004)), so gene expression was simulated using the precomputed GTEx parameter estimates of these
tissues as outlined in Section 3.3.1. Per gene, the mean isoform proportion for each GTEx tissue was
used to calculate a Hellinger distance between all pairwise tissue combinations. Genes were selected to
be simulated for each tissue if the Hellinger distances to all other tissues were greater than 0.1. Isoform
expression was simulated for 50 samples with 100 genes simulated from cerebellum, 100 genes simulated
from liver, 50 genes simulated from spinal cord, 50 genes simulated from tibial nerve, and 25 genes
simulated from pancreas. Additionally, 25 genes were simulated as a mixture of the two brain tissues.
These genes were selected based on having a Hellinger distance less than 0.4 between the two brain
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tissues and distances to all other tissues greater than 0.8. The Dirichlet parameters for these 25 genes
were then randomly chosen as coming from either cerebellum or spinal cord. Gene expression was
simulated using a Negative Binomial distribution with size = 20 and µ = 200. Conditional on total gene
expression, isoform expression was allocated per gene following the Dirichlet Multinomial distribution
with parameters estimated from GTEx. Supplementary Figure B.51 shows a visual representation of this
simulation setup.
Figure 3.9: a) Multinomial posterior estimates for the probability vector for tissue membership (φ)
using a simulated dataset of 50 samples fitting the model with ten gene classes. Annotation bars above
the figure represent the tissue that was simulated and the gene class that was identified by the model.
Columns are genes and rows are the GTEx tissues. b) Hellinger distance between a random sample of
GTEx and a simulated experimental dataset. Points are for each GTEx sample and correspond to the
average Hellinger distance between that sample and each experimental sample.
We subset the reference panel to only the five tissues of interest and fit the model using ten gene
classes. Ten random initializations were run to address the possibility of the model being stuck at a local
maximum. The model with the highest likelihood was chosen as the final model. ACTOR removes genes
that align poorly with all tissues. Of the 375 genes that were given to the model, 369 remained after the
model was fit. Figure 3.9a provides posterior estimates of the probability vector for tissue membership
(φ). Columns are genes with the column annotation bars corresponding to the simulated tissue and
the gene class identified by the model. Rows correspond to the GTEx tissues of interest. Additionally,
Table 3.1 contains posterior Dirichlet estimates (η) of the tissue probability vector for each gene class.
Gene classes 5-10 were empty and therefore are not shown in the table. In both the figure and table, we
demonstrate that we accurately recapture almost all of the tissue assignments that were simulated. Gene
classes were also correctly identified and gene class 4 contains the genes that are uniquely cerebellum,
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uniquely spinal cord, and a mixture of the two. Of the 100 genes that were simulated as coming from liver,
only one gene was incorrectly assigned to the brain gene class. Of the 44 genes that passed the model
filtering and were assigned to be a mixture of the two brain tissues, only two of them were incorrectly
classified with one being assigned to the pancreas gene class and the other to the tibial nerve gene class.
Overall, only 0.8% of genes were incorrectly classified.
Tissue Gene Class 1 Gene Class 2 Gene Class 3 Gene Class 4
Cerebellum 0.04 0.04 0.04 123.94
Liver 0.04 99.04 0.04 0.04
Pancreas 26.04 0.04 0.04 0.04
Tibial Nerve 0.04 0.04 51.04 0.04
Spinal Cord 0.04 0.04 0.04 69.14
Table 3.1: Posterior Dirichlet estimates (η) for the gene class specific tissue probability vector. Gene
Class 4 combined both brain tissues into one group.
Hellinger distances were calculated between each simulated sample and a subset of GTEx consisting
of 100 samples per tissue group. Only GTEx samples from the cerebellum, liver, pancreas, tibial nerve,
and spinal cord were used and distances were calculated using the same set of genes as ACTOR to allow
for a more even comparison. The average distance from each simulated sample to each GTEx sample
was calculated. For each GTEx sample, the average distance to the simulated samples was calculated and
plotted (Figure 3.9b). From the figure, it is difficult to determine which tissues most closely aligned with
the experimental samples. The results of this analysis do not include a gene-based interpretation and
thus one possible interpretation of this analysis is that the experimental dataset did not align with liver or
pancreas. This was likely due to the small number of genes that were aligned to these tissues, however
this demonstrates that a probabilistic model may better capture the per gene alignment as well as provide
a more concrete conclusion regarding splicing similarity.
The previous simulation involved simulating data using parametric assumptions with parameters
informed by GTEx data: Negative Binomial total gene expression and Dirichlet Multinomial isoform
expression. An additional simulation was conducted using GTEx isoform expression as the experimental
set, combining data from two tissues to form a hybrid simulated sample. Genes that had between two
and five expressed isoforms were included in this analysis. Half of the genes were randomly assigned
to be spleen and the other half to liver. Expression for these genes was obtained by randomly selecting
the isoform expression directly from 100 GTEx samples from the corresponding tissue. In this setting,
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Figure 3.10: a) Posterior estimates for the probability vector for tissue membership (φ) using a dataset
of 100 samples generated from a mixture of GTEx liver and spleen tissues. Annotation bars above
correspond to the simulated tissue and the gene class identified by the model. b) Hellinger distance
between a random sample of GTEx and a simulated experimental dataset containing spleen and liver
genes. Points are for each GTEx sample and correspond to the average Hellinger distance between that
sample and each experimental sample. The red bar identifies the liver GTEx samples and the blue bar
identifies the spleen GTEx samples.
expression is not simulated parametrically as done in the first simulation, but rather as sample mixtures
of existing GTEx samples. Supplementary Figure B.52 shows a visual representation of this simulation
setup. Variances were calculated for the proportion estimates of each isoform and a gene was removed
from the analysis if the sum of isoform proportion variances was below 0.001 to remove genes that were
similar to all GTEx tissues. Before the model was fit and per gene, a pre-model posterior probability was
calculated using the log-likelihood of each tissue. For each tissue, the sum of the pre-model posterior
probabilities was calculated across all genes and the tissue with the smallest posterior probability sum
was removed from the analysis. This process was continued until only five tissues remained. This
was done to reduce the dimension of our model. After these filters were done, a total of 1975 genes
remained. The model was fit using ten gene classes and ten random initializations. Figure 3.10a provides
the posterior estimates of the probability vector for tissue membership. Shown by the annotation bars
above the figure, the model correctly identified all genes to be of the correct tissue. Table 3.2 provides
the Dirichlet estimates for four of the ten gene classes. The six remaining gene class were empty and
are not shown in this table. The model identified two non-empty gene classes that correspond to genes
that aligned to liver and spleen, gene class 1 and 2 respectively. Only five of the 818 genes that were
simulated to be liver were incorrectly classified while only two of the 1157 genes that were simulated to
be spleen were incorrectly classified. Overall, only 0.4% of genes were incorrectly classified.
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Tissue Gene Class 1 Gene Class 2 Gene Class 3 Gene Class 4
Liver 815.09 0.09 0.09 0.09
Prostate 0.09 3.54 0.09 0.09
Small Intestine 0.09 5.47 0.09 0.09
Spleen 0.09 114.82 0.09 0.09
Colon 0.09 3.21 0.09 0.09
Table 3.2: Posterior Dirichlet estimates (η) for the gene class specific tissue probability vector. Gene
class 2 contains all genes that aligned to spleen, while gene class 3 contains all genes that aligned to liver.
Gene classes 5-10 were empty and thus are not shown.
Hellinger distances were again calculated using 100 samples of each GTEx tissue. Only genes that
were included in the reference panel model were included. Figure 3.10b provides the average distances
with colored bars to identify the spleen and liver tissues. A full version of this plot with an attached
legend is available in Supplementary Figure B.53. Spleen is correctly identified as a top tissue; however,
it does not appear that liver aligns well with this experimental dataset. This could be explained by the
fact that liver cells exhibit some of the most distinct splicing patterns, relative to the other GTEx tissues.
It is possible that genes that were not simulated to be liver had vastly different splicing patterns and
thus resulted in a very large distance with all liver GTEx samples. When aggregating across genes, it
is possible that liver would no longer appear similar to the experimental dataset as the larger distances
would outweigh the smaller ones. It is important to note that we have constructed hybrid samples that do
not naturally appear in GTEx. This will inherently provide challenges for the distance-based approach
and will favor ACTOR.
3.3.3 Spinal Cord RNA-seq Data
Isoform expression from an experiment analyzing lumbar spinal cord sections (Batra et al. (2016))
was analyzed using our probabilistic model. The isoform expression for 8 non-ALS patients was
quantified using Salmon (Patro et al. (2017)) with Gencode 19 to ensure that the quantified transcripts
matched the set from GTEx. Only genes with two to five annotated isoforms were included for this
analysis. The top 5 tissues were selected in the same manner as outlined in the previous simulation. A
large number of genes were not similar to any GTEx tissue. This resulted in the selection of tissues with
the largest variance rather than biologically accurate tissues. To combat this, genes were removed if they
had an average log-likelihood across the experimental samples less than -10. The requirement of this
filtering presents a limitation of the current model and future work could address this issue. The model
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Figure 3.11: a): Posterior estimates for the probability vector for tissue membership (φ) using a real
dataset of 8 motor neuron samples. b): Hellinger distance between a random sample of GTEx and motor
neuron samples. Points are for each GTEx sample and correspond to the average Hellinger distance
between that sample and each experimental sample. The blue bar identifies the brain GTEx samples.
was fit using ten gene classes. Multiple gene classes were not found in the analysis of the spinal cord
dataset. Our model aligned a large portion of the genes to the brain regions, amygdala and cerebellum,
which was expected given the nerve composition of the lumbar spinal cord sections (Figure 3.11a).
Supplementary Figures B.54 and B.55 provide heatmaps of individual genes that align to the amygdala
and cerebellum respectively. Supplementary Figures B.56 - B.61 provide similar heatmaps for genes that
aligned to liver, heart, and muscle. These heatmaps demonstrate that none of the reference panel groups
are similar to the experimental dataset and that a decision is being made based on the reference group
with a large variability. To ensure that the results are not driven by gene expression, a heatmap of the
median gene expression for the GTEx tissues is given in Supplementary Figure B.62. This heatmap is
column and row ordered identically to Figure 3.11a and does not regenerate the clustering seen in Figure
3.11a, demonstrating that ACTOR’s gene grouping is not driven by total gene expression.
Hellinger distances were calculated between each spinal cord sample and the GTEx samples, with
100 samples selected per tissue as before. The average distance was calculated (Figure 3.11b). A full
version of this plot with an attached legend is available in Supplementary Figure B.63. Brain samples
consistently provided small distances which would suggest that our experimental samples are most
similar to brain. This is as expected; however, this analysis does not provide a gene level interpretation
and thus it is unknown if the alignment to brain is common across all genes or merely a subset.
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3.4 Discussion
We have constructed a probabilistic model similar to LDA to compare one or more samples associated
with a high dimensional vector of features — here the isoform expression patterns of RNA-seq samples
— to groups in an independent reference panel. We demonstrated the effectiveness of our model through
simulations constructed from the GTEx project dataset, and using Dirichlet Multinomial distributions
defined by GTEx tissues as a reference panel. Our model correctly identified genes and gene classes for
which isoform splicing was similar across tissues in two simulation settings. While our model was able
to accurately recapture the simulated tissue, Hellinger distances were shown to only provide summary
level interpretations. We showed qualitatively how distances could identify similar tissues but were not
able to identify gene specific similarities.
In our evaluations, the model performs well in situations where the gene classes have orthogonal
tissue probability vectors. However, our simulations involved generating hybrid samples as a proof of
concept which could overly favor our method. Additionally, we only looked at genes with a small set of
isoforms and implemented filtering thresholds for both genes and tissues. Future work could address
these concerns to utilize a larger proportion of the data and to provide more statistically rigorous ways
of removing genes. If the number of gene classes is over specified, the method will output empty gene
classes however it is important to not underestimate the number of gene classes or the method will
collapse all of the gene classes into one. Future work could address this issue and determine a more
rigorous way of identifying the number of gene classes needed.
In our analysis of motor neuron samples comparing to GTEx, genes that were similar to all GTEx
tissues or similar to none of the GTEx tissues aligned to tissues with the largest variance. This presents
potential issues when utilizing an experimental dataset and reference panel that are not similar. Our
model also failed to identify distinct gene classes. GTEx samples are collected post-mortem, while the
spinal cord samples were extracted from living donors. It is possible that RNA degradation may affect
quantification of isoform expression that confounded the alignment of the spinal cord samples to GTEx
tissues that occurred when Dirichlet Multinomial likelihoods were computed with the fixed parameters
estimated on GTEx samples. Other reference panels could be used to examine this claim. Additionally, it
is possible that larger sample sizes could help in the estimation of gene classes.
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Our model can also be used as a way to describe functional changes for genes that were found to
be differentially spliced. After a DTU analysis, the genes with evidence for DTU can be passed to our
model, fitting posterior probabilities separately for the treatment and control groups. Results from the
two models could be qualitatively compared to identify if the isoform switching also led to changes in
the alignment of sample sets to reference groups. Our model could be extended into a full differential
analysis of sample sets with respect to reference panels. Here our model was fit using a variational
Bayes procedure for maximum efficiency, however a Gibbs sampling procedure may provide more
stable results at the trade-off of computation time. The R package actor also allows for the inclusion
of other reference panels and takes as input a matrix of precomputed Dirichlet estimates or a matrix of
precomputed log-likelihoods.
3.5 Software Availability
ACTOR is implemented as an R package actor which is publicly available at https://github.
com/mccabes292/actor. All of the scripts used in the analyses presented in this manuscript can be
downloaded from the following respository: https://github.com/mccabes292/actorPaper.
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CHAPTER 4: SQWCCA - SAMPLE QUALITY WEIGHTED CANONICAL CORRELATION
ANALYSIS
The work in this chapter was motivated through collaborations with Dr. Terry Furey, Dr. Shehzad
Sheikh, Dr. Karen Mohlke and Dr. Ben Keith. Variable sample quality of biological samples can
affect the results of any bioinformatics analysis. In RNA-seq datasets, the transcript integrity number
(TIN) measures the RNA degradation (Wang et al. (2016)) and the Transcription Start Site (TSS)
enrichment score can be used to determine the signal to noise ratio in ATAC-seq datasets (Ou et al.
(2018)). Researchers may heuristically remove samples based on an arbitrary cut point of these scores
prior to any formal analysis and without data-driven knowledge of the need for their removal. We can
identify a sample’s quality by identifying samples that provide outlying results within Sparse CCA. One
approach would be to identify points that fall off of the diagonal of the contribution plot, however, this
could result in removing high quality samples and artificially inflating the relationship between the two
assays. These results would suffer from overfitting and be less generalizable. We instead use the results
of Sparse CCA and an external quality score to determine a sample’s weight. We also utilize a cross-
validation scheme to identify a solution that does not suffer from overfitting. We propose Sample-Quality
Weighted Canonical Correlation Analysis (SQWCCA) as an extension of Sparse Canonical Correlation
Analysis that utilizes an external covariate to inform sample weighting. To simplify the complexity of
this problem, we will focus on settings with only two assays. Due to the additional challenge of varying
quality of multiple assays, we also assume that only one of the assays is of variable sample quality.
SQWCCA leverages the results from Sparse CCA to uniquely determine a sample’s quality through the
use of an external covariate. This ensures that SQWCCA identifies sample weights that provide optimal
correlations, without suffering from overfitting. However, we do not expect SQWCCA to greatly improve
the correlation from Sparse CCA or to identify a different set of feature loadings as the main purpose of
SQWCCA is to identify samples of lower quality. We evaluate SQWCCA on several simulation scenarios
and in a real dataset containing RNA-seq and ATAC-seq for samples of Crohn’s disease patients and
other patients who do not have inflammatory bowel disease.
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4.1 Model
We begin by defining X1 and X2 as n× p1 and n× p2 matrices where n corresponds to the number
of samples and pm corresponds to the number of features in data type m. In genomics settings it is
common to have “tall” matrices representing assay data, with the features (e.g. genes for RNA-seq) as
rows and the samples as columns. However, to be consistent with the Sparse CCA notation (Witten and
Tibshirani (2009)), we have chosen a “wide” data representation with samples as rows. Let βm be a pm x
1 vector corresponding to the loadings for data type m. Additionally, let zi be the external quality score
for sample i. In Chapter 2, we defined the sample contribution for data types 1 and 2 as X̃1i = β′1x1i
and X̃2i = β′2x2i. Finally, let W be a diagonal matrix with the sample-specific weights w = (w1, ..., wn)
along the diagonal. To eliminate computational burdens associated with deriving sample weights and
feature loadings simultaneously, we only use the contributions from a pre-computed Sparse CCA analysis
to derive the sample weights. Sample weights are chosen such that they maximize the weighted correlation








. A table for
all notation in this chapter is available in Supplementary Table C.6.
Corrw(X̃1, X̃2) =
∑n
i=1wi(X̃1i − X̄1w)(X̃2i − X̄2w)√∑n
i=1wi(X̃1i − X̄1w)2
∑n
i=1(X̃2i − X̄2w)2 (4.12)
We modeled the weights, wi as a logistic function of the quality score zi, with two parameters
controlling the slope and inflection point (See (4.13)). We therefore assumed that the quality is an
increasing function of the quality score, that eventually saturates and approaches a weight of 1. We chose
a parameterization of the logit link that allowed for a more interpretable solution, as seen in (4.13). In this
parameterization, γ corresponds to the slope of the curve, and α corresponds to the inflection point. This
allows the user to interpret α as a rough estimate of the cut point for the quality score, when the sample
is contributing to the Sparse CCA solution about half of a full quality sample. Figure 4.12 provides an
intuitive visualization of the method.
wi =
exp{γ(zi − α)}
1 + exp{γ(zi − α)}
(4.13)
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Figure 4.12: SQWCCA uses the contributions from Sparse CCA and a Quality Score to learn sample-
specific weights that maximize the correlation between the contributions.
A penalty parameter was also added on the weights to avoid degenerate solutions. Without the
penalty parameter, setting the weights to nearly zero for all samples except for the samples with the top
two quality scores could result in a correlation of nearly 1. We also seek to remove samples only if there
is substantial evidence for their removal, as such a penalty is placed on (1− wi) instead of wi in contrast
to SWCCA. With this penalty added, the full objective function can be seen in Equation 4.14.
∑n








The L2 penalty on the weights was chosen over the L1 penalty for several reasons. First, the L2
penalty provides a differentiable objective function for faster optimization, described in the next section.
Second, the logit link on the weights implicitly defined a continuous relationship between the sample
weights and the quality score. An L1 penalty will force weights to 0 which could impose a strict cut-point
on the quality score. In practice, this would cause γ to become very large in order to appropriately capture
the split between included and excluded samples creating computational challenges for optimization.
Finally, we wished to characterize sample quality as a continuous measure with samples receiving weights
between 0 and 1 rather than a stronger claim of whole inclusion and exclusion of samples, as could result
from L1 penalization schemes.
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4.2 Model Fitting
We optimized Equation 4.14 using a Limited-memory Broyden Fletcher-Goldfarb-Shanno algorithm
with boxed constraints (L-BFGS-B,Byrd et al. (1995)), to identify α and γ that maximize the objective
function. The efficiency of our fitting procedure improved when provided the first derivative of the
objective function, shown in Supplementary Section C.2. The unconstrained optimization raised two
computational issues. First, we note that an α value greater than the second largest quality score resulted
in low weights for all samples except for the sample with the largest quality score. Second, an analysis
where all samples should have received a weight of 1 identified an α approaching −∞ as the optimal
solution. To avoid these situations, we set the maximum bound for α to be equal to the second largest
quality score and the lower bound for α to be equal to 10 standard deviations of the original quality score
below the lowest quality score. Quality scores were scaled to have mean 0 and variance 1 which allowed
for common definition of bounds across quality scores with varying scales. In simulated data, we found
that larger values of γ yielded rougher and more difficult objective functions to optimize. However, by
setting the maximum bound of γ to be 10, we were still able to identify the value of α that maximized
the objective function. We assume that the sample’s value in contributing to the Sparse CCA solution is
increasing monotonically with the quality score, where a larger value is considered as a good quality
sample and a smaller value is considered as a poor-quality sample. We therefore set the lower bound of γ,
the slope of the logistic function, to be 0. If the user has a decreasing quality score where smaller values
indicate higher quality, the negative of this score can be used instead. To ensure that the optimization did
not obtain a local maximum, 20 random initializations were performed and the α and γ that provided the
maximum correlation were chosen. The above optimization procedure was performed with a fixed value
for λ. Large values of λ set all weights to 1, whereas small values of λ resulted in degenerate solutions
as described above. The value of λ must be carefully chosen in order to obtain reasonable results.
4.3 Weighted Matrices
The weighted correlation can also be written as a correlation between two weighted vectors. We now
show the derivation for obtaining the explicit expression of the weighted vectors. First, we write out X̄1w,
the weighted mean for data type 1, as a vector and write out the decomposition as an expression of the
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sample-specific weights, w, and the contributions for data type 1, X̃1, in matrix notation in 4.15. This










We then rewrite the difference between each sample’s contribution for data type 1, X̃1i, and the
weighted mean for data type 1, X̄1w, in matrix notation as follows.
(X̃1 − X̄1w) = (I − (1′w)−111′W )X̃1
= AX̃1
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Finally, we rewrite the numerator of the weighted correlation using the results above, where W 1/2 is
a diagonal matrix with the
√
wi along the diagonal.
n∑
i=1



















Therefore, assuming fixed sample weights, we transform the original matrices, X1 and X2, into
weighted matrices by multiplying them byW 1/2A. As we will see in the following section, these matrices
now be used in Sparse CCA during the process of selecting the optimal tuning parameter.
4.4 Estimating Tuning Parameters
To find the optimal tuning parameter for the sample weights, we implemented a 50/50 data splitting
approach averaging over 100 random splits. This can be described using the following algorithm for each
candidate λ.
1. For s ∈ 1, ..., S, where S is some large number of permutations (e.g. hundreds),
(a) Randomly split the samples into 50% training and 50% testing
(b) Using the training samples, find the optimal weights (w) using SQWCCA (Optimizing
Equation 4.14 )
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(c) Weight the original data types using the training weights from (b)
(d) Re-run Sparse CCA, obtain the estimated loadings for each data type (β̂s1 , β̂
s
2)
(e) Calculate the training set contributions (β̂s1)
′X1(−s) and (β̂s2)
′X2(−s)
(f) Calculate the correlation between the training set contributions ρsλ




λ and the standard deviation of the test set
correlations (ŝdλ).
A tuning parameter bound is chosen by selecting the λ with the largest mean test set correlation
and subtracting one standard deviation (ρ̂λMax − ŝdλMax). The optimal tuning parameter is chosen
to be the smallest λ such that the mean test set correlation is larger than the tuning parameter bound
(λOpt = min{λ : ρ̂λ ≥ ρ̂λMax − ŝdλMax}). This is a variant of the 1 standard error rule (Hastie et al.
(2008)), except instead of favoring large values of λ to induce a sparse solution, as in LASSO, here we
favor small values of λ to induce sample weight sparsity.
4.5 Data Preparation
4.5.1 Simulations on TCGA data
TCGA breast cancer samples (The Cancer Genome Atlas Research Network et al. (2013)) were used
as the basis for the simulations. RNA counts for 58,037 genes were obtained from recount2 (Collado-
Torres et al. (2017)) and the pre-normalized miRNA-Seq was collected for 305 miRNAs (Hoadley et al.
(2014), Wong et al. (2019)). A variance stabilizing transformation (Anders and Huber (2010)) was
applied to the size factor scaled counts for RNA. In total, 558 breast cancer samples were used. Previous
work has shown that Sparse CCA applied to this data reveals strong correlations between the two assays
with the RNA contributions being correlated with the expression of ESR1 (McCabe et al. (2019)).
Four separate simulation settings were used to evaluate SQWCCA, across various scenarios with
informative and non-informative quality scores (Summarized in Table 4.3). Simulation 1 used all 558
breast cancer samples and a randomly generated quality score. The quality score was non-informative
and was randomly generated from a normal distribution with mean 0 and variance 1. In this simulation,
the ideal weights are expected to be close to 1 for all samples as the randomly generated quality score
does not provide information as to the removal of samples that do not provide value in contributing to the
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correlation of the Sparse CCA solution. For Simulation 2, 5% of the RNA samples were replaced with
randomly generated samples. Samples were generated from a normal distribution and were scaled and
centered to have the same mean and variance as the original sample. The quality score was randomly
generated from a normal distribution and ordered so that the randomly generated, and therefore “low
quality”, samples had the smallest quality scores. We expected SQWCCA to set low weights for the
lowest 5% of samples by quality score, by finding α and γ such that the logistic curve separates the
original and randomly generated samples. Simulation 3 used the same RNA samples as Simulation 2;
however, the quality score was a non-informative randomly generated value from a normal distribution
with mean 0 and variance 1. Since the weights are learned from the non-informative quality score, we
expected SQWCCA again as in Simulation 1 to provide weights close to 1 for all samples. For the
final simulation, we employed down-sampling of counts to induce lower quality, and made use of the
final library size as an indication of sample quality. In RNA-Seq analyses, the total read count will be
inversely associated with the variance of the log scale counts across samples, such that low total read
counts may be associated with lower quality samples. We induced lower quality in 10% of RNA samples,
by down-sampling the samples to have a total read count of 10,000 reads compared to an average original
read count of 77 million reads and then applied VST to the new set of counts (original samples and
down-sampled samples). In each of the four simulations, the miRNA normalized data was kept in its
original state.
In practice, we found that dimension reduction prior to the application of Sparse CCA resulted in
more stable results that did not overfit on the training data (See Chapter 2). Therefore, for all simulations,
the RNA dataset was reduced to the top 5,000 most variable genes prior to the analysis. Sparse CCA
was first performed and the assay-specific contributions were calculated. SQWCCA was then performed
on the contributions using the appropriate quality score. The optimal tuning parameter was selected as
outlined above.
Sim Data Quality Score Expected Outcome
1 Full Data Non-Informative Random High weights for all samples
2 5% Random for RNA Informative Random Low weights for the 5% of Samples
3 5 % Random for RNA Non-Informative Random High weights for all samples
4 10% Down-weighted for RNA Total Read Counts Low weights for the 10% of samples
Table 4.3: Simulation Setup
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4.5.2 Crohn’s disease and non-IBD
RNA-seq and high-throughput measurements of chromatin accessibility (ATAC) were collected for
108 samples from Crohn’s disease (“CD”) patients and other patients who do not have inflammatory
bowel disease (“non-IBD”) as in a previous study (Weiser et al. (2018)). Samples were taken from
non-inflamed regions of the colon. RNA-seq reads were counted across 57,821 genes. Genes on the
Y chromosome and mitochondrial genes were removed from the analysis which left 57,032 genes.
Additionally, ATAC-seq reads were counted for 97,133 peaks. Peaks on the Y chromosome were also
removed which left 97,040 peaks. In practice, we found that subsetting to the top 5,000 most variable
features in each assay resulted in more stable results which did not overfit on the training set data. Sparse
CCA was then performed on the two assays. Using the contributions from this analysis, SQWCCA was
performed with the Transcription Start Site (TSS) enrichment score, a measure of the signal-to-noise
relationship for ATAC-seq, as the sample quality score. Through exploratory data analyses, ATAC-seq
was the assay that was found to have the most variable sample quality, which motivated the use of the
TSS score as the sample quality score.
4.6 Results
4.6.1 Simulations on TCGA data
In simulated datasets, SQWCCA did not overfit on non-informative quality scores but was able
to detect meaningful relationships between sample quality and informative simulated quality scores.
Table 4.4 provides the values of α, γ, and the tuning parameter (λ) for each simulation. Additionally,
Supplementary Figures C.64-C.67 provide the plots of the cross-validated correlation by the log of the
tuning parameter. These plots were used in each simulation to determine the optimal value of the tuning
parameter (λ).
The contribution plot from the full Sparse CCA analysis for simulation 1 can be seen in Figure
4.13a. Figure 4.13b plots the sample weights against the quality score. As seen in this plot, none of the
samples have a weight close to 0 which indicates SQWCCA did not identify a relationship between the
non-informative quality score and the sample weights and did not overly down-weight samples.
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Figure 4.13: Simulation 1: a) Contribution plot for the full analysis and b) plot of the derived weights by
the randomly generated quality score. Dotted line is placed at the value of α (-4.34).
In Simulation 2, we used an informative randomly generated quality score that was ordered such
that the 5% of samples with randomly generated data received the smallest quality score. In Figure
4.14a, the contribution plot shows that the poor-quality samples appear off the diagonal and the overall
correlation would improve with the down-weighting of these samples. The results of our analysis can be
seen in Figure 4.14b. SQWCCA appropriately down-weighted samples that had a low-quality score and
improved the overall correlation from 0.858 to 0.893. We also note that the value of α (-1.75) is very
close to the largest quality score value of the randomly generated samples (-1.68) and thus SQWCCA
was able to find reasonable parameters for the logistic curve.
Simulation 3 utilizes the same contribution plot as Simulation 2. In this setting, we used a non-
informative randomly generated quality score. Supplementary Figure C.68 shows that SQWCCA
identified a weight close to 1 for nearly all samples. This demonstrates that SQWCCA will not down-
weight samples unless they are associated with accordingly low-quality scores.
In our final simulation, we down-sampled raw counts from the RNA-seq matrix and used the total
counts as the associated quality score. The contribution plot (Figure 4.15a) also shows that down-
sampled samples will lower the overall correlation and should be considered for removal. After running
SQWCCA, the weights identified a clear split between the down-sampled and original, unmodified
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Figure 4.14: Simulation 2: a) Contribution plot for the full analysis and b) plot of the derived weights by
the ordered quality score. Red points correspond to samples that have random RNA-seq. Dotted line is
placed at the value of α (-1.75).
Sim λ α γ
1 0.078 -4.34 0.98
2 0.548 -1.75 6.86
3 0.114 -8.31 0.55
4 0.217 2.18e7 3.09e-7
Table 4.4: Simulation Results: λ is the optimal tuning parameter for the simulation, α can be interpreted
as the cut point for the quality score, and γ is the slope for the relationship between the quality score and
the weights.
samples by successfully setting weights to near 0 for all the down-sampled samples (Figure 4.15b). While
the value of α is not particularly close to the total read counts for the poor samples (10,000), it is still
below the smallest total read count for the good samples (28.7 million counts). This is due to the large
differences in the read counts of the “high” and “low” quality samples as well as to the existence of
multiple parameter values that equally separate these samples.
4.6.2 Crohn’s disease and non-IBD
In the analysis of Crohn’s disease samples, SQWCCA was able to identify low quality samples that
improve the overall correlation between ATAC-seq and RNA-seq. Contribution plots for the Crohn’s
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Figure 4.15: Simulation 4: a) Contribution plot for the full analysis and b) plot of the derived weights by
the total read counts. Red points correspond to samples that were down-sampled. Dotted line is placed at
the value of α (2.18e7).
disease samples are available in Figure 4.16a. The optimal tuning parameter was found to be 0.134
(Supplementary Figure C.69). After performing SQWCCA, the correlation increased from 0.870 to 0.889.
Six samples were assigned weights less than 0.25 (Figure 4.16b). The estimates for α and γ are 6.61 and
1.96 respectively. To further investigate the effect of these samples on the overall analysis, we ran Sparse
CCA on the set of samples excluding the 6 samples with low weights. Contribution plots (Supplementary
Figure C.70) show a slight improvement in overall correlation between the full contributions, weighted
contributions, and the reduced analysis contributions but do not indicate a large change in the ordering of
the samples as was expected. Samples are colored by subtype and show that NIBD samples tended to
have larger contributions for both RNA-seq and ATAC-seq. Examination of the loadings, the feature level
output from Sparse CCA, for each data type (Supplementary Figure C.71a) shows that the RNA loadings
maintained their ordering in the full analysis and in the analysis without the six down-weighted samples,
while the ATAC-seq loadings had some minor fluctuations in their values (Supplementary Figure C.71b).
This indicates that the six samples only slightly influenced the results of the full analysis.
SQWCCA accurately identified low quality samples in both a completely artificial simulation and
in a more realistic simulation. Additionally, SQWCCA did not overfit in situations in which there was
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no relationship between the simulated quality score and the sample’s quality, even in settings in which
the removal of samples would improve the overall correlation. In real data, we found that SQWCCA
identified six samples that were potentially of low quality.
Figure 4.16: Real Data: a) Contribution plot for the full analysis and b) plot of the derived weights by the
TSS enrichment score. Dotted line is placed at the value of α (6.61). Red points correspond to the six
samples that were identified with low weights.
4.7 Discussion
In this chapter we proposed SQWCCA as an extension of Sparse Canonical Correlation Analysis
that utilizes an external quality score to identify sample weights that increase the weighted correlation. In
simulations where a meaningful quality score was used, our method accurately identified low weights
in the correct range of quality scores. In simulations where a non-informative quality score was used,
SQWCCA did not suffer from overfitting. In real data, we identified six samples that could be of lower
quality and could be considered for removal.
We acknowledge a few limitations to SQWCCA. First, SQWCCA is only able to handle the analysis
of two data types. While this is a limitation of the method, we could extend the method to multiple data
types by re-defining the objective function as the sum of the weighted correlations between each pairwise
comparison of the assays (as in Sparse CCA). A more challenging limitation of the proposed work is
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that we assume that only one of the data types is of variable sample quality. Accounting for variable
sample quality across multiple data types is a more challenging task and thus was not addressed in this
work, however future work could address these limitations. One approach is to run SQWCCA twice
using a quality score for each assay and then to compare the weights across the two analyses to indicate
problematic samples in each or both assays. If there are multiple quality scores for one assay, SQWCCA




In this document we proposed several approaches for the analysis of multi-omics and multi-study
datasets. In Chapter 2, we proposed a statistical framework for the evaluation of multi-omics methods
(MOVIE) in terms of consistency and degree of overfitting. We evaluated PC-CCA, Sparse mCCA,
AJIVE, and MOFA and found that all methods performed well with a large-sample dataset, while sparse
mCCA and MOFA showed some overfitting in the small-sample dataset. We also proposed ACTOR, A
latent Dirichlet model to Compare expressed isoform proportions TO a Reference panel as a probabilistic
model for comparing isoform splicing patterns from an independent experimental dataset with those
in a reference panel containing a predefined grouping of samples. For each gene, our model identifies
a mixture of reference groups with similar characteristics. Our model also identifies sets of genes in
the independent sample which have similar mixtures. We demonstrated the effectiveness of our model
in two simulation setups and a real dataset. Finally, we proposed Sample Quality Weighted Canonical
Correlation Analysis (SQWCCA) as an extension of Sparse CCA. SQWCCA leverages results from
Sparse CCA to derive sample quality weights through the use of an external covariate. In simulations,
we accurately recaptured poor quality samples and did not overfit when random non-informative quality
scores were used. In a real data set we identified six samples of low quality in an analysis of RNA-seq
and ATAC-seq collected for samples from patients with Crohn’s disease and other patients who do not
have inflammatory bowel disease.
Future work could include an expansion of the methodology in Chapter 2 to allow for the incorpora-
tion of multiple sets of weights within the evaluation framework. In Chapter 3, future work could address
the identification and handling of genes which aligned to none of the reference groups and future work
for Chapter 4 could allow for variable sample quality across multiple assays. Additionally, Chapter 4
could be expanded to allow for more than two assays to be used.
As the availability of multi-omics and multi-study datasets becomes more prevalent, adequate
statistical models must be created to appropriately analyze these types of data. As models become more
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complex, it is vital that method evaluation develops along with method development to ensure the validity
and accuracy of conclusions. In addition to the development of more sophisticated method evaluation,
multi-omics methods which can allow for assays to be missing for a set of individuals also provide a
promising future. Interest in relationships across a large number of assays requires the collection of
a sufficient set of individuals for all assays. This collection can be expensive if the number of assays
is large and will result in the removal of samples which are only collected for a subset of the assays.
Method development which allows for samples to be collected for only a subset of the assays can help
address this issue.
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APPENDIX A: SUPPLEMENTARY MATERIALS FOR MOVIE
A.1 Large Sample Size - TCGA Data
Supplementary Figure A.17: Sparse mCCA with experimental data: Side-by-side contribution plots for
gene expression versus miRNA using Sparse mCCA.
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Supplementary Figure A.18: Sparse mCCA with experimental data: Side-by-side contribution plots for
CNV versus miRNA using Sparse mCCA.
Supplementary Figure A.19: Sparse mCCA with experimental data: Side-by-side contribution plots for
CNV versus gene expression using Sparse mCCA.
re
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Supplementary Figure A.20: MOFA with experimental data: Side-by-side contribution plots for gene
expression versus miRNA using MOFA.
Supplementary Figure A.21: MOFA with experimental data: Side-by-side contribution plots for CNV
versus miRNA in experimental data using MOFA.
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Supplementary Figure A.22: MOFA with experimental data: Side-by-side contribution plots for CNV
versus gene expression using MOFA.
Supplementary Figure A.23: AJIVE with experimental data: Side-by-side contribution plots for gene
expression versus miRNA using AJIVE.
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Supplementary Figure A.24: AJIVE with experimental data: Side-by-side contribution plots for CNV
versus micro RNA using AJIVE.
Supplementary Figure A.25: AJIVE with experimental data: Side-by-side contribution plots for CNV
versus gene expression using AJIVE.
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Supplementary Figure A.26: Sparse mCCA with experimental data: Comparison plots for CNV, gene
expression, and miRNA using Sparse mCCA.
Supplementary Figure A.27: MOFA with experimental data: Comparison plots for CNV, gene expression,
and miRNA using MOFA.
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Supplementary Figure A.28: AJIVE with experimental data: Comparison plots for CNV, gene expression,
and miRNA using AJIVE.
Supplementary Figure A.29: Contribution correlations for AJIVE for each pair of data sets in an analysis
with increased ranks for CNV.
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Supplementary Figure A.30: Pairwise plots of RNA contributions for a) Sparse mCCA vs. AJIVE, b)
MOFA vs. AJIVE, and c) MOFA vs. Sparse mCCA
Supplementary Figure A.31: Pairwise plots of CNV contributions for a) Sparse mCCA vs. AJIVE, b)
MOFA vs. AJIVE, and c) MOFA vs. Sparse mCCA
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Supplementary Figure A.32: Pairwise plots of miRNA contributions for a) Sparse mCCA vs. AJIVE, b)
MOFA vs. AJIVE, and c) MOFA vs. Sparse mCCA
Supplementary Figure A.33: Plot of expression of ESR1 gene against the RNA contribution for a) Sparse
mCCA, b) MOFA, and c) AJIVE.
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A.2 Small Sample Size - Li et al, 2016
Supplementary Figure A.34: MCCA with small-sample dataset: Contribution plots for DNase and Protein
expression using MCCA.
72
Supplementary Figure A.35: MCCA with small-sample dataset: Contribution plots for DNase and gene
expression using MCCA.
Supplementary Figure A.36: MCCA with small-sample dataset: Contribution plots for protein expression
and gene expression using MCCA.
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Supplementary Figure A.37: MOFA with small-sample dataset: Contribution plots for DNase and protein
expression using MOFA.
Supplementary Figure A.38: MOFA with small-sample dataset: Contribution plots for DNase and gene
expression using MOFA.
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Supplementary Figure A.39: MOFA with small-sample dataset: Contribution plots for protein expression
and gene expression using MOFA.
Supplementary Figure A.40: AJIVE with small-sample dataset: Contribution plots for DNase and protein
expression using AJIVE.
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Supplementary Figure A.41: AJIVE with small-sample dataset: Contribution plots for DNase and gene
expression using AJIVE.
Supplementary Figure A.42: AJIVE with small-sample dataset: Contribution plots for protein expression
and gene expression using AJIVE.
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Supplementary Figure A.43: MCCA with small-sample dataset: Comparison plots for DNase, protein
expression, and gene expression using AJIVE.
Supplementary Figure A.44: MOFA with small-sample dataset: Comparison plots for DNase, protein
expression, and gene expression using AJIVE.
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Supplementary Figure A.45: AJIVE with small-sample dataset: Comparison plots for DNase, protein
expression, and gene expression using AJIVE.
Supplementary Figure A.46: Comparison plots of contributions from Sparse mCCA for the 3 fold
analysis.
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Supplementary Figure A.47: Comparison plots of contributions from Sparse mCCA for the 10 fold
analysis.
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A.3 Permuted Null Data
Supplementary Figure A.48: MOFA with null data: Side-by-side contribution plots for miRNA versus
gene expression using MOFA.
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Supplementary Figure A.49: AJIVE with null data: Side-by-side contribution plots for miRNA versus
gene expression using AJIVE.
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APPENDIX B: SUPPLEMENTARY MATERIALS FOR ACTOR
B.1 Supplementary Tables
j ∈ {1, ..., n} sample index
g ∈ {1, ..., G} gene index
l ∈ {1, ..., C} gene class index
s ∈ {1, ..., T} reference group index
i ∈ {1, ..., Ig} isoform index for gene g
ω Dirichlet parameter for gene class probability vector of length C
γ gene class probability vector of length C
cg gene class membership for gene g (vector of length T with a 1 in the position for
the
designated gene class and 0 else)
β Dirichlet parameter for the reference group probability vector of length T
θl reference group probability vector of length T for gene class l
tg reference group membership for gene g of length T
αgs precomputed Dirichlet estimate for gene g of the s reference group of length Ig
pgj isoform probability vector for sample j of gene g of length Ig
Ngj total gene expression for sample j of gene g
Xgj isoform expression for sample j of gene g of length Ig
ηl Dirichlet parameter for the variational distribution of the reference group proba-
bility
of length T
vector for gene class l (θl)
φg reference group probability vector of length T for gene g of the variational
distribution
λg gene class probability vector of length C for gene g of the variational distribution
ρ Dirichlet parameter of length C for the gene class probability vector (γ)
Supplementary Table B.5: Notation for ACTOR
B.2 Supplementary Methods
B.2.1 Variational Inference
Here we describe the derivation of the variational inference estimation procedure. First, we calculate
the full joint likelihood of our model by multiplying the conditional probability distributions as shown in
Equation B.16. We can integrate out p to get the Dirichlet Multinomial distribution which models the
isoform expression for each biological sample. This replaces p(Xgj |pgj)p(pgj |tg) with p(Xgj |tg) in
our joint likelihood (Equation B.16).
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Our hope is to find p(θ, t, c|X,β, γ); however this requires the calculation of p(X|β), which is
intractable. We instead look to find a “candidate” distribution for our full likelihood and try to estimate
the parameters of this distribution which allows the candidate and full likelihoods to be similar. This
procedure is known as variational inference (Jordan et al. (1999)) and the derivation for this can be seen
in Equation B.17. We begin by writing out the observed log-likelihood. Here, the isoform counts (X) are
the only observed component of our likelihood, so we integrate or sum all other latent variables out of
the full joint likelihood. We then multiply the numerator and denominator by our candidate distribution,
q(θ, t, c), and write the likelihood as an expectation with respect to our candidate distribution q. Finally,
we apply Jensen’s Inequality to move the log inside of the expectation and reduce to the difference in the
expectation of our full log-likelihood with respect to our candidate distribution and the expectation of our
candidate distribution. This is often called the variational lower bound or evidence lower bound (ELBO)
and maximizing this lower bound is equivalent to minimizing the Kullback-Leibler divergence between
the full and candidate likelihoods.



































Next we write out the full likelihood by taking the expectation as outlined above.












Eq [log p(cg|γ)] +
C∑
l=1
Eq [log p(θl|β)] + Eq [log p(γ|ω)]
Eq[log(q(θ, t, c, γ))] =
C∑
l=1













Eq [log p(Xgj |tg)] +
G∑
g=1
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Inverting H is found by application the Sherman-Morrison inverse formula.
Estimation of ω is done similarly.
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B.3 Supplementary Figures
Supplementary Figure B.50: Toy example of potential gene classes. Columns correspond to gene classes
with each gene class containing a potentially different number of genes. Rows correspond to the groups
from the reference panel. Gene class 1 aligns with reference group 1, gene class 2 aligns with reference
group 2, and gene class 4 aligns with reference group 5. Gene class 3 is shown to be equally similar to
reference groups 3 and 4.
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Supplementary Figure B.51: Diagram of data generation for Simulation 1. Using the precomputed
Dirichlet estimates of the reference panel, a per gene Hellinger distance is calculated on the mean isoform
proportion between liver, tibial nerve, spinal cord, cerebellum, and pancreas tissues. Genes are considered
for the simulation from a given tissue if the Hellinger distance to all other tissues is greater than 0.1.
Additionally, genes which had a Hellinger distance between the spinal cord and cerebellum tissues less
than 0.4 and greater than 0.8 to all other tissues were considered for simulating as a mixture of the
two tissues. Gene expression was simulated for all genes using a Negative Binomial distribution with
size = 20 and µ = 200. Isoform expression for each gene was simulated by drawing from a Dirichlet
Multinomial conditioned on the fixed total gene expression. In total 350 genes were simulated with 100
from liver, 50 from tibial nerve, 50 from spinal cord, 100 from cerebellum, 25 from pancreas, and 25
from a mixture of cerebellum and spinal cord.
Supplementary Figure B.52: Diagram of data generation for Simulation 2. 50 liver and 50 spleen samples
were randomly selected from the GTEx dataset. A hybrid sample was created by randomly selecting half
of the genes with 2-5 annotated isoforms as being liver with the other half being spleen. Genes were then
removed if the isoform patterns were similar across all GTEx tissues.
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Supplementary Figure B.53: Hellinger distance between a random sample of GTEx and a simulated
experimental dataset containing spleen and liver genes. Points are for each GTEx sample and correspond
to the average Hellinger distance between that sample and each experimental sample.
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Supplementary Figure B.54: Heatmap of the isoform proportions for gene ENSG00000108797.7, which
aligned to amygdala. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
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Supplementary Figure B.55: Heatmap of the isoform proportions for gene ENSG00000122484.8, which
aligned to cerebellar. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
94
Supplementary Figure B.56: Heatmap of the isoform proportions for gene ENSG00000064419.9, which
aligned to liver. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
95
Supplementary Figure B.57: Heatmap of the isoform proportions for gene ENSG00000047932.9, which
aligned to liver. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
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Supplementary Figure B.58: Heatmap of the isoform proportions for gene ENSG00000101474.7, which
aligned to heart. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
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Supplementary Figure B.59: Heatmap of the isoform proportions for gene ENSG00000106244.8, which
aligned to heart. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
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Supplementary Figure B.60: Heatmap of the isoform proportions for gene ENSG00000112584.9, which
aligned to muscle. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
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Supplementary Figure B.61: Heatmap of the isoform proportions for gene ENSG00000114999.7, which
aligned to muscle. Each column corresponds to an isoform of this gene with the rows corresponding
to either a tissue group from GTEx or an experimental sample indicated by the first annotation bar.
Cells are the estimated isoform proportions for GTEx tissues and the observed isoform proportions for
experimental samples. The second annotation bar shows the posterior estimate from the model for the
tissue group membership. The last annotation bar is the inverse precision for the GTEx tissue for this
gene. Experimental samples will not have a value for the last two annotation bars.
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Supplementary Figure B.62: Heatmap of the median gene expression of each GTEx tissue used in the
real data analysis. Each column is a gene and each row is a GTEx tissue. Cells are the log transformed
gene expression. Rows and columns have been ordered in the same order as Figure 7 from the main text.
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Supplementary Figure B.63: Hellinger distances between a random sample of GTEx and motor neuron
samples. Points are for each GTEx sample and correspond to the average Hellinger distance between that
sample and each experimental sample.
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APPENDIX C: SUPPLEMENTARY MATERIALS FOR SQWCCA
C.1 Notation
n Number of samples
p1 Number of features in data type 1
p2 Number of features in data type 2
X1 n x p1 Matrix of data type 1 (e.g. RNA)
X2 n x p2 Matrix of data type 2 (e.g. ATAC)
β1 p1 x 1 vector of loadings for data type 1
β2 p2 x 1 vector of loadings for data type 2
X̃1 n x 1 vector of contributions for data type 1 from Sparse CCA (X1β̂1)
X̃2 n x 1 vector of contributions for data type 2 from Sparse CCA (X2β̂2)
Z n x 1 covariate vector for sample quality (TSS Score)
W n x n diagonal matrix with the samples weights (wi) along the diagonal
w n x 1 vector of the sample weights (the diagonal of W).
λ Sparsity parameter to push sample weights to 1
X̄1w Weighted mean of the contributions for data type 1
X̄2w Weighted mean of the contributions for data type 2
Supplementary Table C.6: Notation for SQWCCA
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C.2 Derivative of Objective Function
L = Corr(X̃1, X̃2,W )− λ(1−W )′(1−W )
Corr(X̃1, X̃2,W ) =
∑n
































































































(X̃1i − X̄1w)(X̃2i − X̄2w)− wi
∂X̄1w
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Supplementary Figure C.64: Plot of the Cross-Validated Correlation by the log of the tuning parameter λ
for Simulation 1.
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Supplementary Figure C.65: Plot of the Cross-Validated Correlation by the log of the tuning parameter λ
for Simulation 2.
Supplementary Figure C.66: Plot of the Cross-Validated Correlation by the log of the tuning parameter λ
for Simulation 3.
108
Supplementary Figure C.67: Plot of the Cross-Validated Correlation by the log of the tuning parameter λ
for Simulation 4.
Supplementary Figure C.68: Simulation 3: Plot of the derived weights by the randomly generated quality
score. Dotted line is placed at the value of α (-8.31).
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Supplementary Figure C.69: Plot of the Cross-Validated Correlation by the log of the tuning parameter λ
for Real Data.
Supplementary Figure C.70: Real Data Contribution Plots: Contribution plots for the real dataset using
the full data (a), the weighted data (b), and after removing the 6 low quality samples (c). Red points
correspond to NIBD samples and black points correspond to Crohn’s samples.
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Supplementary Figure C.71: Comparison of Sparse CCA Loadings: Comparison of Sparse CCA loadings
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